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IH LITHIUM PSYCHOPHARMACOLOGY 
Since sleep disturbance is often a prominent as¬ 
pect of affective illness, it is important to assess 
how changes in mooa relate to changes in sleep pattern 
occurring at the same time. Assessment of changes in 
psychobiologic patterns (such as sleep, levels of 
activity, or appetite and weight fluctuations) may 
provide a way of classifying the type and severity of 
affective disorder, and of predicting response to a 
specific mode of treatment. The rationale for extend¬ 
ed electroencephalographic (EEG) sleep studies in 
affective illness lies in providing such a method. 
In general, reports on the relationship between 
sleep disturbance and depression have demonstrated a 
decreased total sleep time, due mainly to intermittent 
wakening and early morning arising. Also shown is a 
decrease in slow-wave sleep (stages three and four),2^ 
Both increases and decreases in REM sleep time have 
been reported 3b, 39__a difference which may reflect 
25 
different types of depressive illness. v Other stud- 
22 1 
les of sleep disturbance in schizophrenia and mania 
- J..-1 
. 




have shown that while total sleep time is also de¬ 
creased., the difference is due more to difficulty 
falling asleep than to increased intermittent wake¬ 
fulness or early morning awakening. Similarly, al¬ 
though REM sleep time is also decreased, there is a 
marked tendency toward prolongation of REM sleep 
latency, in contrast to the foreshortening of REM 
latency in depression.Furthermore, while sleep 
during the period following a manic episode may 
show an increase above normal of REM sleep time,^f 
sleep during the waning phase and postpsychotic 
period of acute schizophrenic illness does not show 
pp 
a rebound. ^ 
Despite these apparent differences, it is not 
entirely clear that a given form of sleep attrition 
or sleep-stage rearrangement is specific to a given 
affective illness, rather than being a non-specific 
concomitant of a troubled psyche. Similarly, it is 
not clear that drug effects on the sleep of manic- 
depressive or schizophrenic patients are necessarily 
related to the biochemical basis of their therapeutic 




to deal directly with these two issues. 
2b 
A recent report by Kupfer and Heninger is par¬ 
ticularly illustrative. It is the first longitudinal 
EEG sleep investigation of a patient with a 48-hour 
cyclic mood disorder. The regularity and magnitude of 
change in symptoms permitted observation of the period 
of actual mood change, rather than of depressive or 
manic episodes per se. The study is an attempt to find 
an objective indication of depressive illness and to 
correlate changes in specific sleep parameters with 
changes in clinical severity. 
The patient was a 70-year old male with a four- 
year history of a 48-hour cyclic change in mood. The 
cycle consisted of two 24-hour periods, the first 
period characterized by depressed mood, motor retarda¬ 
tion, and social withdrawal; and the subsequent 24-hour 
period by mild elation, increased motor activity, and 
social involvement. The largest changes in mood were 
observed to occur between 7 p.m. and 7 a.m. These 
changes were assessed by nurses' ratings completed 
daily over four four-hour periods. A self-rating scale 
was also used at various times. The daily changes in 
. 
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symptoms were reported to be largest on the nurses' rat¬ 
ings of depression, lack of subjective energy, social 
withdrawal, and motor retardation. Since a much greater 
degree of depression was present than of mania, the case 
probably presents a model for a depressive episode which 
lifts every twenty-four hours, rather than for bipolar 
illness. 
Sleep periods prior to depressed days ("D-nights") 
were compared to those prior to hypomanic days 
("M-nights"). The main differences between the two 
periods were increased early morning awakening (p 0.001, 
paired t-test) and decreased REM activity on D-nights 
(p ^ 0.001). Both early morning awakening and REM ac¬ 
tivity were significantly correlated to the a.m. depres¬ 
sion ratings: r=0.63 (p 0.05) and r= -0.73 (p<l 0.01), 
respectively. 
To evaluate the possibility that significant cor¬ 
relations might exist between mood and particular sleep 
variables at different times of the night, sleep param¬ 
eters were compared by thirds of nights. Compared to 
M-nights, total sleep time was significantly greater on 
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but was much reduced during the last third (p 0.01). 
Similarly, during the final third of D-nights, other 
sleep parameters were significantly reduced (p O.Ol), 
including REM time, intensity of REM activity (REM 
activity units per minute of sleep time), and sleep 
period utilization. 
The authors report further that the extent of de¬ 
pressed mood was inversely correlated to the amount of 
hourly REM activity during D-periods, and that the ex¬ 
tent of mood elevation was positively correlated to the 
amount of hourly REM activity during M-periods. Since 
the hourly changes can be shown to correlate signifi¬ 
cantly either to depressed periods or to non-depressed 
periods separately, the authors infer that the correla¬ 
tion is a characteristic of the depression itself, 
rather than a reflection of cyclicity. 
To test whether the alteration in REM activity 
merely reflected the change in mood or was itself re¬ 
sponsible for changes in mood, the patient was sub¬ 
jected to a REM deprivation protocol. He was 
first REM-deprived on a night when he was switching 
from a depressed to a hypo-manic day; then he was 
• . t,. ixJ i t aH r uiijj.Xonx 
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allowed, one night of recovery, followed by two consecu¬ 
tive nights of REM-deprivation, and completed by two 
nights of recovery. The authors note that the patient 
showed no REM rebound on the recovery nights and that 
no change in his mood cycle occurred. They suggest 
that changes in REM parameters may be reflective of, 
rather than causally related to, mood changes. 
It is interesting that the sleep pattern of the 
D-nights resembled that of uni-polar depression in 
general (as described by Mendels and Hawkins‘S, and by 
Kupfer et, al«^), with decreased nonREM sleep, short¬ 
ened REM latencies (the amount of time asleep until the 
onset of the first REM period), and increased awakening 
with especially marked early morning awakening. Further¬ 
more, the sleep pattern before an M-day was consistent 
with that described for the recovery-phase sleep in uni¬ 
polar depression—with relatively little early morning 
awakening, and "normal" REM time and activity through¬ 
out the night. Mendels and Hawkins have reported also 
that delta sleep is increased in remission, although it 
may not reach levels of normal controls.^ In Kupfer*s 
ph 
study‘s the increase in delta sleep time on M-nights is 
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not statistically significant. This apparent lack of 
rebound may be a reflection of the patient's age, as 
suggested by all-night sleep studies on normal, elderly 
adults.9’ 20 
Sleep in patients with manic-depressive illness 
has not been as thoroughly investigated as in patients 
with unipolar psychotic and recurrent depressions. The 
first published report‘d was a study of six manic-de¬ 
pressive patients on whom a total of 162 all-night sleep 
EEG recordings were made. The study was conducted under 
less than ideal circumstances—in most cases while pa¬ 
tients were living at home, as well as during hospital¬ 
ization. Patients were studied in three different set¬ 
tings, and methods of clinical assessment were not uni¬ 
form for the entire group. During hospitalization each 
patient slept in the sleep laboratory only once per 
week, although occasionally more often during acute 
situations. Electromyograms were obtained in only two 
cases. Patients were also given somatic treatment when 
indicated. Two had a brief course of EOT, while two 
received chlorpromazine at various times during the 
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Intrapatient comparisons showed that total sleep time 
was always lowered during manic phases. Total sleep time 
during depressed periods varied, but overall was un¬ 
changed, or slightly greater, than during normal 
periods. REM time was "definitely low" during manic 
periods and tended to be higher than normal during de¬ 
pressed periods. The hypermanic periods showed the 
lowest REM sleep time, while the very depressed periods 
showed the highest. REM latency was reported to vary 
greatly during manic periods, but appeared "definitely 
low" during depressed periods. Stage four sleep time 
also varied considerably; overall it was "very slightly 
low" during manic phases, and "low" during the "very 
depressed" periods, but not low during the milder de¬ 
pressions . 
The author expressed surprise at finding a ten¬ 
dency towards increased sleep time in the depressed 
periods, since earlier reports had indicated hyposomnia 
in depressed patients. The finding has been confirmed, 
O 
however, by at least two later studies. Detre et. al,° 
studied QU bipolar and unipolar depressed patients by 
means of a questionnaire, to determine whether they 
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showed symptoms of increased sleep time. In brief, 
they found that patients with bipolar depressions 
(i.e., patients in whom depression alternated with 
mania) slept longer (p^. 0.001, chi square analysis) 
and more restfully (p £ 0.01) but felt worse in the 
morning (p^ 0.05) than patients with unipolar de¬ 
pression. Further comparison between hypersomnic and 
hyposomnic depressed patients showed that hyposomnia 
was associated with difficulties in falling asleep 
(P< 0.001), with middle-of-the-nignt awakening 
(P< 0 .05) and with early-morning awakening (p ^ 0.05). 
On the other hand, hypersomnia was significantly associ¬ 
ated with an increase in weight (p 4. 0.05), with feeling 
worse in the morning (p ^ 0.05), and with a greater fre¬ 
quency of hospitalization (p < 0.05). 
25 
In a second report, Kupfer et. al. ^ confirmed the 
finding of significantly different sleep patterns in 
bipolar and unipolar depressed patients. The EEG sleep 
patterns of nine bipolar or cyclothymic patients re¬ 
porting hypersomnia were compared with those of seven 
unipolar depressed patients reporting hyposomnia. The 
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two psychiatrists and by a patient self-rating symptom 
form ("KDS-l": Psychological Reports: 24: 607-17, 1971). 
Five of the nine hypersomnic patients had not received 
any psychoactive drug for at least three weeks prior to 
the study; the other four were receiving maintenance 
lithium carbonate treatment at the time that they became 
depressed. The hyposomnic group (all inpatients) had 
likewise not received any psychoactive medication for 
three weeks prior to the study. 
With the exception of REM time and wakefulness 
(which were lower at the 0.05 level in the untreated 
hypersomnic group), both hypersomnic groups—-treated 
(maintenance lithium) and untreated—showed similar 
results. Similarities noted were in time spent asleep, 
total non-REM sleep, individual sleep stages 1-4, sleep 
latency, intermittent wakefulness, early morning awaken¬ 
ing, REM time, REM activity, and REM latency. In addi¬ 
tion, the group on maintenance lithium showed sleep 
changes compatible with those described for acute 
lithium treatment^ ? such as increased REM latency and 
increased delta sleep, but none of these changes was 





hypersomnic patients or the hyposomnic patients. 
Both groups of bipolar depressed patients differed 
significantly from the unipolar depressed group in time 
asleep (total sleep period minus wakefulness; p<£ 0.001) 
and in non-REM sleep. The latter difference was due 
primarily to an increase in stage 2 sleep (p ^ 0.001). 
Similarly, both hypersomnic groups showed a significant 
increase in sleep period utilization (p ^0.05), a find¬ 
ing consistent with the anergia associated with bipolar 
patients. When the data was further examined for in¬ 
fluences of differences in age, sex, and prior hospital¬ 
izations, the results were essentially unchanged. In 
summary, all sleep stages in bipolar depression showed 
an increase commensurate with the increased net sleep 
time; that is, the relative stage percentages were simi¬ 
lar in all three groups. Only stage-2 sleep showed an 
absolute increase of statistical significance. This 
finding contrasts with the observation of Hartmann 
1 h 
et. al, who described a significantly greater REM 
sleep percentage in so-called normal long sleepers as 
compared to short sleepers. An interesting possibility 
suggested by this study is that the different psycho- 
•' 
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biologic patterns characteristic of unipolar and bi¬ 
polar affective disorders may well reflect basic genetic 
or biochemical differences. 
An important theoretical and clinical implication 
of observed psychobiologic differences among affective 
disorders is that of drug effect on these differences. 
Ideally, one would like to use the different abnormali¬ 
ties of sleep or activity patterns as indications for 
specific anti-depressant or anti-manic therapy (tri¬ 
cyclic, tricyclic plus phenothiazine, MAO inhibitor, 
lithium, MAOI plus lithium, EOT). The indication would 
be strengthened if certain drug-induced changes in psy¬ 
chobiologic patterns were found to correlate with clini¬ 
cal improvement. Although lithium carbonate therapy 
and prophylaxis is now recognized as more or less ef¬ 
fective in various affective states, very little in¬ 
vestigation into its effect on the sleep of psychiatric 
patients has been reported. There are at least three 
recent reports which, taken together, provide evidence 
that lithium probably does exert significant influences 
upon the electrical activity of brain and CNS function. 
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whether EEG changes are concomitant with clinical im¬ 
provement and, if so, which changes are specifically 
associated with improvement and which are non-specific. 
In addition to these studies, there are only two other 
recent reports of investigations into the effect of 
lithium on sleep in normal and psychiatric patients. 
Mayfield and Brown^ reported a daytime EEG study 
on six actively manic patients and five control pa¬ 
tients without affective illness, the latter being 
diagnosed as passive dependent and inadequate person¬ 
alities. Serum lithium levels were monitored and main¬ 
tained between 0.7 and 2.0 mEq/liter. EEG’s were re¬ 
corded twice weekly, approximately two hours after 
serum lithium determination. The time of the blood 
sample in relation to administration is nowhere stated, 
and it may be questioned whether the authors reported 
the false-high values of a post-ingestion absorbtive 
peak. Nor are the methods of clinical rating or EEG 
scoring described. It is not clear whether the study 
was open or double-blind, and no control tests with 
placebo therapy were conducted . 
Wine patients completed the study (U manic. 
.:.i 1f»S • '9 • • 
- 




5 control). All individuals showed definite EEG changes 
from normal baseline records. Slowing of the dominant 
rhythm and slight increase in amplitude were the earliest 
changes. In the non-activated, resting records, the mean 
lithium serum level of the first change was 1.19 mEq/liter 
(range= 0.76 to 1.98). This contrasts with Schou's find¬ 
ing^ that the minimum therapeutic and prophylactic effect 
of treatment necessitates a serum lithium concentration of 
at least 0.6 to 0.8 mEq/liter. The EEG changes once 
present progressed with increasing serum levels (reported 
as a clinical impression). Potentiation of amplitudes 
continued, and background rhythm became progressively 
more disorganized. Slowing progressed with the appear¬ 
ance of randomly distributed theta and delta activity. 
Paroxysmal, bilaterally synchronomous delta activity 
was seen in three patients. No attempt was made to 
quantify these changes and compare control with patient 
groups. Mean serum lithium level at which all EGG 
changes were first noted was 1.69 mEq/liter 
(range=1.00 to 2.U1). The records returned to base¬ 
line promptly as serum levels fell, although there was 





. •). - -> f ' 
15 
lagging behind the falling serum levels for several 
days. The authors conclude tnat such profound EEG 
changes (unaccompanied by focal neurological changes 
or more evidence of alterations in other organ systems) 
could not be produced on any other basis than as an 
alteration in the ion-exchange mechanism in the CNS. 
One might add that it is still not clear whether 
EEG changes are a necessary concommitant of lithium’s 
therapeutic action. Nor is it evident whether the pro¬ 
duction of abnormal slow waves (in conjunction with 
various reported changes in ionic flux, catecholamine 
and corticosteroid levels) provides any clue to the 
mechanism of action, or is rather an indication of a 
generalized reaction to the high, at times toxic, 
serum levels achieved. 
The investigation reported by Platman and Fieve^ 
permits at least a partial answer to the questions 
raised by the work of Mayfield and Brown, Forty-five 
patients with long histories of recurrent manic and/or 
depressive attacks were selected for this double-blind 
study, EEG's were taken on admission and discharge. 
Clinical states were assessed with rating scales and 
■J 
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various self-reporting forms. Patients were assigned 
randomly to placebo, chiorpromazine, imipramine, or 
lithium therapy. Twenty-eight patients had both 
placebo and lithium recordings; of these, fifteen 
showed increasingly abnormal EEC's on maintenance 
lithium therapy. Abnormalities were similar to those 
reported in the earlier study: slow-wave activity, 
accentuated by hyperventilation. While no attempt 
was made to assess quantitatively the degree of ab¬ 
normality, it was the authors' impression that there 
was no difference in the amount of EEG abnormality 
for any of the three clinical states (normothymic, 
manic or depressive). This was said to be true of 
the H6 recordings taken during the placebo period 
and for all other recordings taken while patients 
were on different medications. Further analysis 
showed no significant difference in sex distribution, 
mean age, mean serum lithium level, duration of 
lithium therapy, or clinical state, between the 15 
patients whose EEC's showed changes and the 13 pa¬ 
tients whose EEG's did not. The authors conclude 





therapeutic action of lithium. 
The conclusion is not strictly warranted by the 
data, however, since clinical histories for the par¬ 
ticular patients in the two lithium groups are not 
presented. A t-test of mean improvement rates in each 
group would be required to establish the conclusion. 
There may be some plausibility in the inference, how¬ 
ever, since mean serum lithium levels in both groups 
(0.86 t 0.17 mEq/liter in the group with unchanged 
EEC's, and 0.78 4 0.23 mEq/liter in the group with 
changed EEG's) were within the accepted therapeutic 
range. 
^8 
A third investigation by Small et. al. was con¬ 
ducted to establish whether neurophysiological changes 
observed in manic-depressive patients on lithium 
therapy were related primarily to the drug itself, or 
were influenced by psychobiological factors such as 
clinical state, mood change, and response to treatment. 
EEG's,evoked responses, and direct-current potential 
activities were obtained before treatment and after 
three weeks on lithium, given in the usual maintenance 
doses, follwed by a placebo. Slight, but significant 
• ■ ■ 
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slowing (p^ 0.001, paired t-test) of dominant back¬ 
ground frequencies occurred with lithium in both pa¬ 
tients and normal controls. The slowing did not 
entirely resolve itself two to five days post-lithium 
withdrawal. Paroxysmal EEG slowing appeared more often 
in normal volunteers than in patients. Auditory evoked 
potential findings were similar in the two groups. 
Some visual evoked response latencies were shorter 
after lithium in the normal subjects, whereas the pa¬ 
tients displayed no significant latency changes. On 
the other hand, the manic-depressive patients did show 
evoked-potential amplitude variations with lithium 
therapy, while the normal controls did not. The D-C 
responses of the normals did not show pronounced nega¬ 
tive potential D-C changes, but the patients on the 
drug showed significant changes in both positive and 
negative directions. The authors propose no unifying 
hypothesis to explain the observed differences, but 
conclude tentatively that lithium probably does exert 
a significant influence upon the electrical activity 
of brain and ClfS functioning in the range of therapeutic 




EEG changes are associated, with clinical improvement, 
while others may be only nonspecific, is not evident 
from the data presented. 
The first reported investigation into the effect 
of lithium carbonate on sleep failed to find any sys¬ 
tematic drug effects on the EEG sleep patterns of 
three controls and three remitted manic-depressive 
patients.^ The study has been criticized by Kupfer 
et. al. ^ on the ground that serum lithium levels in 
any of the six subjects were never greater than O.U9 
mEq/liter, whereas levels of 0.6 to 0.8 have been 
shown to be the minimal requirement for effective 
therapy and prophylaxis, with greater levels often 
required. Kupfer et, al.^3 repeated the study using 
therapeutic levels of lithium. 
Seven patients were selected, each having been 
evaluated on the basis of independent agreement by 
three psychiatrists. Six were in the manic or hypo- 
manic phase of bipolar illness, while one was in a 
psychotic depression. All medications were discon¬ 
tinued at least ten days prior to the study. During 
the study a constant number of idential capsules con- 
• . 




taining either placebo or lithium carbonate (300 mg.) 
was administered. Serum lithium determinations were 
used routinely to maintain blood levels between 0.7 
and 1.30 mEq/liter. Each period of the sleep study 
was comprised of at least three consecutive nights, 
with most being four or more nights. A total of 120 
sleep records was scored according to modified Dement- 
Kleitman criteria by a scorer unaware of the patients' 
drug status. 
Pre-drug sleep patterns were characterized by 
abnormalities similar to those described for mania by 
Hartmann, including reduction in time spent asleep, 
with a commensurate decrease in REM time; prolonged 
REM latency; and almost no delta sleep. During maximum 
drug administration, there was a significant decrease 
in REM percent in all seven patients, from a mean of 
17.7 to 12.h (p ^ 0.001, two-tailed t-test). REM time 
and REM activity were also significantly reduced dur¬ 
ing the drug period ( p K. 0.01). REM latency was con¬ 
sistently prolonged (p ^ 0.01) over pre-drug values. 
Interestingly, a reversal of REM suppression occurred 
in the psychotically depressed patient after discon- 
. 
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tinuation of lithium therapy. Values returned to pre 
drug levels without any indication of compensatory re 
bound. In a second patient who received a moderate 
lithium dosage (1200 mg QD) after a high dosage 
(1800 mg QD), REM time returned to pre-drug levels, 
but the reduction in REM activity levels persisted, 
even with serum lithium levels of only 0.7 mEq/L. 
Delta sleep (stages 3 and 1+), which was almost 
absent in all patients during the placebo period, in¬ 
creased significantly in five patients during the 
drug period (p ^ 0.01). For the remaining two pa¬ 
tients, who were among the oldest of the group, delta 
sleep was entirely absent throughout the study. In 
the one patient in whom lithium carbonate therapy was 
discontinued, delta sleep was then reduced to less 
than ten minutes per night. Also, in one patient, 
higher drug dosage, with increased serum lithium 
levels, was associated with more delta sleep than 
was present with a moderate drug dosage. 
The authors observed a significantly positive 
product-moment correlation between delta sleep and 
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possible interaction between REM sleep and delta sleep 
in the first third of the night, or between the sys¬ 
tems that drive them. Time spent asleep, sleep laten¬ 
cy (sleep onset time), and non-REM sleep time were not 
significantly affected, suggesting that lithium prob¬ 
ably does not have a sedative effect. 
With the exception of the one patient in whom 
lithium therapy was discontinued, the design of 
Kupfer's study permitted only one comparison between 
the placebo and drug periods. Drug periods always 
followed placebo periods. Although the clinical course 
of the patients involved was not presented, the course 
of manic-depressive disease in general is known to be 
variable and somewhat unpredictable. The design em¬ 
ployed may have introduced a bias in favor of episodes 
of short duration, and thus may have distorted the ob¬ 
servation of drug-induced effects on sleep. If the 
first drug period were followed by a second placebo 
period (as it was with one patient), in turn followed 
by a second drug period, then drug effect could be 
more reliably assessed, as it either varies or does 
not vary with the clinical course. 




Kupfer et. al. also observed a lack of REM compensa¬ 
tion in the one patient in whom lithium therapy was 
discontinued. The same patient showed a sharp decline 
in delta sleep after discontinuation of lithium. The 
design for the following investigation should permit 
more observations of the effect of lithium withdrawal 
on REM and delta sleep. The question is whether there 
is a significant, or compensatory, REM sleep rebound 
and/or decline in delta sleep following drug discon¬ 
tinuation. 
The authors reported dose-related effects in the 
one patient who had been on a high dosage followed by 
a moderate dosage. They noted a restoration of REM 
sleep time to pre-drug levels, but a persistent re¬ 
duction in REM activity and intensity levels. A simi¬ 
lar protocol is used in the research to be reported, 
in order to assess a number of such dose-response re¬ 
lationships . 
In addition to all-night or global sleep param¬ 
eters, various REM- and delta-sleep measures are also 
reported by thirds of nights in the different placebo 




exactly does the drug exert its effects on various as¬ 
pects of REM and slow-wave sleep, and [2] what is the 
exact architecture of rebound and withdrawal effects? 
An unusual and perhaps abnormal type of REM sleep is 
also described by thirds of nights. It is character¬ 
ized primarily by a random admixture of beta sleep 
spindles in an otherwise unremarkable REM-type EEG, 
accompanied by the usual REM-type EOG and EMG. A 
second variety of REM sleep abnormality is character¬ 
ized by a high EMG which is not artifact, and which 
subsides to a normal baseline in subsequent REM sleep 
periods. It is argued that these atypical character¬ 
istics may represent drug effects. 
An attempt is made to elaborate on the signifi- 
cantly-positive correlation observed between REM 
latency and delta sleep time. One question is whether 
the correlation is a general one or holds only during 
drug periods. That is, does lithium affect REM sleep 
primarily in the first and second thirds of the night, 
allowing more delta sleep to occur during the earlier 
part of the night? Or does it have a direct, driving 
. .. i. - "■ '• 
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effect upon delta sleep as veil as a directly inhibi¬ 
tory effect upon REM sleep? 
Kupfer also suggested that lithium probably does 
not have a sedative effect. In addition to such 
parameters as net sleep, sleep latency, and non-REM 
sleep time, other factors measuring sedative effect 
are assessed, including intermittent wakefulness, 
early morning arising, and sleep period utilization. 
Finally, an attempt is made to determine if 
lithium has any differential effects upon the sleep 
patterns of manic and depressive patients. One ques¬ 
tion is whether observed similarities or differences 
have implications for the catecholamine hypothesis 
of bipolar affective illness and its proposed mechan¬ 
ism of lithium’s action as a mood normalizer. 
Another, more important, question is whether these 
drug-induced changes, if related to the drug's 
mechanism of action, have prognostic implications 





This study deals with six manic-depressive in¬ 
patients on the psychiatric research ward of the 
Connecticut Mental Health Center (CMHC). Patients 
were selected on the basis of independent evaluations 
by an attending physician and a psychiatric resident. 
In addition, patients were rated at least weekly, and 
sometimes daily, for mania and depression by a psychi¬ 
atrist unaware of the patients’ drug status. Ratings 
were obtained with the use of the KDS-7 psychiatric 
rating scale. As shown in Table 1, five of the pa¬ 
tients were women, ranging in age from 21 to 52, and 
one was a man, aged 39. Two patients (G.H. and C.M.) 
were in a full-blown, manic phase of circular manic- 
depressive illness, while another (L.S.) was in a 
hypomanic stage. Patients M.M. and R.S. had cyclo¬ 
thymic personality disorders, and both were depressed 
at time of admission. The last patient (J.E.) had a 
history of significant thought disorder as well as 
affective derangement, and was diagnosed as schizo¬ 
affective. A brief summary of the psychiatric history 
of each patient follows. 
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G.H. was a 5^-year-old white housewife who had 
had a dozen psychiatric hospitalizations for 
manic episodes in twenty-one years. The first 
attack followed the birth of her second child 
and was characterized by extreme elation, hyper¬ 
activity, and expenditure of large amounts of 
money. The second episode occurred five years 
later. Initially the attacks were more severe 
and lasted as long as six months, while later 
episodes have been less intense, shorter, and 
more frequent. There is no history of depres¬ 
sive episodes between manic attacks. The pa¬ 
tient had done fairly well on lithium carbonate 
therapy for the two years prior to admission. 
The present episode began three weeks before 
admission, when her daily dosage was cut from 
1500 to 900 mg. because of side effects of 
drowsiness, polyuria, fatigue, and muscular 
weakness. Her sleep deteriorated; she became 
irritable, overtalkative, and overactive. She was 
admitted in full-blown mania. Past somatic 
treatment, which met with only limited success, 
included ECT and chlorpromazine. 
L.S. was a 39-year-old white male systems 
analyst who had suffered two episodes of mild 
to moderately severe depression before admis¬ 
sion. The first occurred eight years prior 
to admission at a time the patient was experi¬ 
encing disagreement and discouragement at work. 
The patient reports one short episode of 
suicidal ideation, but appetite, sleeping, and 
social habits remained about the same. He 
consulted a psychiatrist biweekly for six to 
eight months and took Librium on a prn basis. 
The second episode, about six months prior to 
admission, occurred during a period when L.S. 
felt he was being unjustly critized at work. 
He reports feelings of guilt, sadness, and 
worthlessness, out of proportion to the situ¬ 
ation. He stopped having sexual relations 
with his wife, but denies any sleep distur¬ 
bance. About three months later, after he had 
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been praised at work, his mood seemed to 
switch. L.S. renewed sexual relations 
with his wife, switched jobs (without 
good reason), became increasingly flirta¬ 
tious with his secretaries, and had sev¬ 
eral homosexual encounters for the first 
time. Becoming increasingly assertive, 
the patient felt he was "flying ";he 
corresponded with the archbishop about 
helping his daughter to become a choir 
girl, aspired to the Olympic cross¬ 
country skiing team, and began to drink 
more. His wife forced him to see a 
psychiatrist, who referred him to the 
CMHC. At the time of admission, L.S. 
was described as hypomanic, with ex¬ 
pansive but unsystematized delusions 
and no looseness of associations. 
M.M. was a 2U-year-old white, sin¬ 
gle, graduate student, who described three 
episodes of depression before admission. 
Each lasted at least several months and 
was marked by hypersomnia, anergia, and 
weight gain. There was no apparent associ¬ 
ation with life events. For the past two 
years, M.M. has taken amphetamines on a prn 
basis to maintain mood and activity levels. 
During the periods between depression, M.M. 
tends to work hard, become very outgoing 
and sociable, sleep only a few hours per 
night, and remain thin. She had a year of 
psychotherapy in college, and had seen 
another therapist sporadically for the two 
years before admission. The latter started 
her on Elavil and Mellaril one week before 
admission. At the time of referral to 
CMHC, she was moderately depressed. The 
patient was followed intensively by the 







C.M. was a 22-year-old white, unmarried, 
female college student, who presented with a 
history of depression alternating with mania. 
Four years prior to admission, she became in¬ 
creasingly depressed at being rejected by the 
college of her choice. Her sleep increased 
to ten hours per night, and she put on 1+5 
pounds. She started psychotherapy, only to 
end it after one month because the therapist 
"didn't talk enough". About six months into 
the depression, her mood changed abruptly. 
C.M. became insomniac, anorectic, and lost 
25 pounds. She charged a $1+00. telephone 
bill, bought flamboyant clothing, ran away 
from home, and had intercourse with l6 men. 
She "calmed down" spontaneously after four 
months. She was then seen by a psychiatrist 
who made the diagnosis of circular manic- 
depressive illness and started her on lithium, 
chlorpromazine, and biweekly psychotherapy. 
Four months later the patient developed signs 
of depression which did not abate despite 
change of medication to amitryptyline and de¬ 
crease of lithium. C.M. subsequently discon¬ 
tinued her lithium because of blurred vision 
and nausea. She suffered similar attacks of 
hypomania and depression afterward, until 
being referred to the CMHC for further evalu¬ 
ation and intensive lithium therapy. At the 
time of admission she was described as manic. 
R.S. was a 39-year-old white, single, 
female microbiologist who presented with a 
nine-year history of recurrent, incapaci¬ 
tating depressions. The depressions were 
not, apparently, related to life events. 
They have tended to become more frequent, 
characterized by two weeks of depression 
followed by several days of remission. When 
depressed, R.S. feels very dejected and 
guilty, with loss of interest, low self¬ 
esteem, marked inertia, and inability to do 





sleeping most of the time, and has normal to 
increased appetite. In the past two years, 
the patient has tended to become increasingly 
"high" during the intervals between depres¬ 
sions. She becomes garrulous, makes long 
distance telephone calls, and makes plans for 
the future, often unrealistic. 
J.E. was a 21-year-old, single, female 
college student whose mother had been hospi¬ 
talized 20 times for recurrent mania and is 
now on maintenance lithium therapy. Three 
years before admission, following an LSD 
trip, J.E. became confused and frightened 
that someone was trying to hurt her and con¬ 
trol her thoughts and body. She was hospi¬ 
talized and for several months jdisplayed an 
inertness bordering on catatonia, with in¬ 
ability to walk or feed herself and with 
occasional bizarre actions such as walking 
nude through the hall. After 10 months of 
hospitalization (? somatic therapy), fol¬ 
lowed by out-patient psychotherapy, she was 
able to enroll in college and to do well 
scholastically. She tended, however, to be 
isolated, with little social life. She was 
hospitalized again a year later, and at 
that time was referred to the CMHC. J.E. 
was described as shy and distant, with some¬ 
what flat affect, irrelevant and flighty 
speech, and admitting to auditory hallucina¬ 
tions. Because of her mother’s history and 
her own history of affective as well as cog¬ 
nitive disturbance, lithium therapy was 
elected. Wo correlation was seen, however, 
between her steady improvement (with emer¬ 
gence from a psychotic state) and her serum 
lithium levels. The patient continued to 
do well after discontinuation of lithium 
therapy. 
The six patients were studied by continuous nightly 
recordings of their electroencephalogram (EEG), electro- 
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oculogram (EOG), and submental electromyogram (MG). 
All patients slept in their regular hospital rooms. 
Except in the case of L.S., the first two or three 
sleep records were not used, in order to allow accli¬ 
matization to the recording methods. Whether this is 
actually necessary has not yet been documented. A 
total of 23b sleep records were obtained, distributed 
among the six patients as shown in Table 1. At least 
three records, and usually between five and ten, were 
obtained on each patient during an initial placebo 
period (I). A comparable or greater number of records 
was gotten in a subsequent period during lithium car¬ 
bonate therapy (II). For purposes of comparison with 
the placebo period, only those records taken when 
serum lithium levels exceeded O.SmEq/liter were used. 
In four patients (M.M., C.M., R.S., and J.E.), re¬ 
cordings were taken during a third period off lithium 
(III). Again, only those records taken after serum 
lithium levels had returned to zero were used for com¬ 
parison. In one patient (M.M.), recordings were taken 
during a second period on lithium therapy (IV). 
A total of 23^ records was evaluated according 
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to Kales-Rechtschaffen criteria by a scorer who was 
unaware of the patients' drug or clinical status. In 
addition to the EEG categorization of sleep stages, 
each minute of REM sleep was scored on a nine point 
scale (0 to 8) for intensity of rapid-eye movement 
patterns. The sum for the entire night provided a 
measure of REM activity and reflected both the ampli¬ 
tude and number of conjugate eye movements. No 
attempt was made to distinguish between amplitude and 
number of conjugate eye movements as aspects of REM 
activity. REM sleep was also scored as "abnormal" if 
(l) the EEG contained a random admixture of the usual 
low-amplitude, varied-frequency activity and sleep 
spindles (beta activity), or (2) if the EMG showed 
definitely increased amplitude not attributable to 
artifact. Both kinds of REM patterns are distinctly 
atypical. While they have been recognized, no attempt 
has been made to score them heretofore. 
The following sleep parameters were used in com¬ 
paring placebo and drug periods: total recording 
period (TRP), sleep latency (SL: stage - 2 sleep on¬ 
set time), intermittent wakefulness (A), early morning 
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awakening (EMA: time awake between end of sleep period 
and end of recording period), time spent asleep (TSA: 
total sleep time minus intermittent wakefulness and 
early morning awakening), sleep efficiency or sleep- 
period utilization (ratio of time spent asleep to total 
recording period), REM sleep latency (RL: time from 
sleep onset to REM sleep onset), REM sleep time (RT), 
REM sleep activity (RA), REM sleep per cent (R%: REM 
sleep time divided by time spent asleep), REM activity 
quotient (total REM activity divided by time spent 
asleep), abnormal REM sleep time, stages 1-4 (with 
stages 3 and 4 reported as delta sleep), delta percent 
(combined sleep time of stages three and four divided 
by time spent asleep), delta latency (DL: time from 
sleep onset to delta sleep onset), number of REM sleep 
periods, duration of each REM sleep period, and inter¬ 
vals between consecutive REM periods. Comparisons were 
made between placebo and drug periods for each indivi¬ 
dual patient and for the group as a whole. Statistical 
confidence levels on the sleep data of the group were 
determined with a two-tailed (paired) t-test. For 
individual patients, confidence levels were determined 
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from the mean values of a given parameter in placebo 
and drug periods, together with standard deviation and 
sample size (n). Pearsonian correlations were deter¬ 
mined where appropriate in the study of dose-response 
relationships. In addition, the sleep records of each 
patient were divided into thirds of nights, as deter¬ 
mined by a third of the time spent asleep. Various 
delta- and REM sleep parameters were measured by thirds 
of nights for changes between placebo and drug periods. 
Comparisons were made for individual patients and for 
the group as a whole, determining statistical confidence 
levels in the same way as before. All values reported 
represent means plus-or-minus standard deviations. 
All medications were discontinued at least ten days 
prior to the study. A constant number of identical cap¬ 
sules containing either placebo or lithium carbonate 
(300 mg) were given each day throughout the study, with 
the maximal drug dosage of 2^00 mg/2^ hours. Patient 
M.M. was studied on both an 1,800 mg and 1,200 mg/day 
drug schedule. Plasma lithium levels were monitored 
routinely, usually three times per week, and ranged 
from 0.00 to 2.00 mEq/liter. Mean lithium levels are 
reported in Table 1 

35 
Finally, individual patient data was graphed in 
order to show concurrent changes in serum lithium 
levels, clinical ratings (KDS-7), and various sleep 
parameters. 
RESULTS 
As shown in Table 2, comparison of global (all- 
night) sleep patterns in all patients, lithium car¬ 
bonate therapy appeared to have marked effects on cer¬ 
tain REM sleep measures. REM per cent was reduced from 
19.5 to 12.5", reflecting the decrease in absolute 
REM sleep time from 67.4 to 45.5 minutes per night . 
The reduction in REM sleep time cannot be accounted for 
by either reduction in the number of REM sleep periods 
or an increase in the intervals between consecutive REM 
sleep periods. Rather, it reflects an absolute decrease 
in duration of all REM sleep periods individually. This 
decrease was significant only in the first and third REM 
sleep periods of the night. REM sleep latency was con- 
sistently prolonged by 34 minutes during the drug period0. 
Although the reduction in absolute REM sleep activity 
barely fails to reach significance, the REM activity 





sleep, decreased from 37.3 to 19.7 • Abnormal REM 
sleep time increased during the drug period, but not 
significantly. The large standard deviations of mean 
abnormal REM sleep values reflect a number of nights 
during the placebo and drug periods without any abnor¬ 
mal REM sleep. 
Delta sleep was more than doubled during the 
period of lithium carbonate administrationa. Both 
stages three and four showed changes at the 0.05 level. 
None of the various factors which might reflect a seda¬ 
tive effect of lithium (such as time spent asleep, 
sleep efficiency, intermittent wakefulness, early morn¬ 
ing awakening, and sleep latency) changed significantly. 
Also, there was no change in mean total recording period, 
stage 1, or stage 2 sleep. 
As shown in Table 3, comparison of global sleep 
patterns in placebo periods before (i) and after (III) 
lithium administration indicates little evidence of any 
REM compensation in the post-drug period for REM sup¬ 
pression during drug administration. Although REM sleep 
time does increase somewhat in the post-drug period , 




sleep percent. Rather, it may be commensurate with 
the general increase in time spent asleep3. Consis¬ 
tent with this observation is the lack of significant 
change in the number of REM periods, the duration of 
individual REM sleep periods, and the REM sleep latency. 
Similarly, while absolute REM activity shows a slight 
rise in the post-drug period, the ratio of REM activity 
to net sleep (RA/TSA), an index of REM intensity per 
minute of sleep, does not change significantly. The 
absolute amount of delta sleep in the post-drug period 
is somewhat higher than in the pre-drug period, but 
delta percentage is not significantly altered. Again, 
the absolute increase is probably commensurate with the 
increase in net sleep. 
Although the increase in net sleep does reach sig¬ 
nificance, the reduction in sleep onset time does not. 
Sleep efficiency shows improvement which barely falls 
short of statistical confidence. Intermittent wakeful¬ 
ness and early morning awakening decrease, but not sig¬ 
nificantly. These changes may be compatible with 
changes in the clinical ratings of each patient. 
Table 3 is compiled from sleep data of all four 




were obtained (M.M., R.S., J.E., and C.M.). Data to be 
presented shows that three of these patients individu¬ 
ally showed changes similar to that of the group. The 
sleep data of the fourth patient (C.M.), however, was at 
considerable variance with that of the other three. The 
patient's clinical course was also considerably louder, 
making it difficult in her case to distinguish changes 
in sleep reflecting clinical change from those reflec¬ 
ting lithium administration and discontinuation (see 
below). 
Comparison of sleep parameters by thirds of nights 
(Table b) shows that most of. the drug effect takes place 
in the first and second thirds of the night. This is 
true of reductions in both REM time and REM activity. 
The increase in abnormal REM time most nearly reaches 
statistical significance in the second third of the 
night. Similarly, increases in delta sleep time take 
place primarily in the first two thirds of the night. 
These effects on REM and delta sleep of lithium car¬ 
bonate are further supported by observations reported 
in Table 5. No correlation was found between REM per¬ 
cent and delta percent during the initial placebo 
■> 
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period. During lithium administration, however, a 
significantly negative correlation was found 
(r= -0.3^76, DF = 39, pC9.05). In the post-drug 
period, no correlation was found. 
Further comparison of pre-and post-drug sleep 
patterns hy thirds of nights (Table 6) corroborates 
comparison of all-night parameters. There is no 
evidence of REM sleep rebound at any time during 
the night in the post-drug period, as reflected in 
REM sleep time, absolute REM activity, or relative 
intensity of REM activity (RA/TSA). Similarly, post¬ 
drug delta activity showed no change at any time dur¬ 
ing the night, compared with pre-drug delta activity. 
The sleep data of M.M. (Tables 7-8 and Figure l) 
presents some interesting contrasts with that of C.M. 
(Tables 9-10 and Figure 2). With the former, sleep 
records were obtained during two drug periods as well 
as two placebo periods. The relative stability of 
M.M.'s clinical course throughout all four periods 
(Figure l) permits a clear-cut assessment of lithium's 
effect on her sleep. Comparison of sleep patterns dur¬ 
ing the initial pre-drug period (i) with those during 
. 
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the first drug period (II) shows the same changes mani¬ 
fested by the group as a whole. These include reduc¬ 
tions in REM sleep time e , REM period durations d , 
REM percent ~ , absolute REM activity ^ , and relative 
intensity of REM activity^ ; as well as increases in 
delta sleep time ^ and delta percent' . REM sleep 
latency, abnormal REM time, and abnormal REM activity 
also increased during drug administration, but not sig¬ 
nificantly. As seen in Table 8, all changes occurred 
mostly during the first third of the night. Finally, 
there were no significant changes in time spent asleep, 
intermittent wakefulness, early morning awakening, 
sleep latency, or other factors which might reflect a 
sedative effect of lithium. 
Comparison of pre- and post-drug periods (I and 
III) shows a return of post-drug REM and delta par¬ 
ameters to pre-drug levels. There is no evidence of 
REM sleep compensation or delta sleep withdrawal in 
comparisons within either whole-night (Table 7) or 
third-night sleep patterns (Table 8). 
When M.M. was started on lithium therapy a second 






changes relative to the preceding placebo period (ill), 
as were shown during the initial drug trial (II). This 
time, however, she was placed on a moderate lithium 
dosage (1200 mg./day), and her mean serum lithium level 
was down by an average of 0.26mEq/liter. 
The drug-induced changes were also proportionally less. 
Reduction in REM sleep time, REM percent, and REM activi¬ 
ty were significant at the 0.01 level, rather than at 
0.001 as before. Similarly, drug-induced increase of 
delta sleep time was significant at the 0.05 level, 
rather than at 0.001. It is also interesting that on 
the moderate rather than high dose (cf. values of I and 
IV), REM time and REM percent showed more of a ten¬ 
dency to approximate pre-drug values a than did REM 
activity, which remained low^ . This apparently 
greater sensitivity of phasic REM activity to serum 
lithium levels is further shown by comparing the two 
drug periods (p-values for comparison of II and IV 
not shown). REM activity is significantly greater 
on a moderate drug dosage, but REM time and REM per¬ 
cent are not. 





for a second placebo period, but not for a second drug 
period. In contrast to the relative stability of M.M.'s 
clinical course, that of C.M. changed profoundly between 
the pre- and post drug periods (Figure 2). The change 
in sleep pattern between the two is also quite remark¬ 
able (Tables 9-10). The changes in sleep measures dur¬ 
ing lithium administration were largely consistent with 
those shown by other patients, including suppression of 
REM sleep time and REM percent3 and increase of delta 
sleep time and percent f . Again, these changes took 
place mostly in the first two-thirds of the night. Of 
interest is the apparent suppression of delta sleep 
during the pre-drug period, when C.M. was in a manic 
phase. Administration of lithium was associated with 
both an increase in delta sleep time and a decrease in 
mania ratings (Figure 2). During several days when 
the patient suffered an attack of mania, her serum 
lithium levels dropped below 1.00m Eq/liter, (despite 
daily dosage increase to 2i*00 mg.) and her delta sleep 
time plummeted. As serum lithium levels rose again, 
clinical ratings improved and delta sleep time in¬ 
creased. Concurrently with a later reduction in dos- 




age, C.M.’s manic ratings did not rebound, but in¬ 
stead moved towards clinical depression. Delta 
sleep time also declined, but not as precipitously 
as before. During the post-drug period, when the 
patient was moderately depressed, her net sleep 
time increased by two hours per night^ over the 
pre-drug period, when she was manic. REM time 
e 
more than doubled during the post-drug period, 
an increase due not only to the lengthening of 
the first two REM periods of the night(aand e , 
respectively) but also to an increase in the total 
number of REM periods. Similarly, both absolute 
REM activity and relative intensity of REM activity 
increased in the post-drug period. Delta sleep 
time increased by fifteen minutes3 
It is not clear what the increases in REM sleep 
parameters represent. An argument can be made that 
they are rebound phenomena. Some of the increase is 
commensurate with the increase in net sleep time. 
Since the latter was not suppressed by lithium, the 
increase of over two hours per night in the post¬ 






C.M.'s clinical state, rather than to drug withdrawal. 
This inference is consistent with her history of hyper¬ 
somnia during depressed periods. Not all of the REM 
sleep increase can be accounted for by the increase in 
net sleep, however, since REM percent itself increased. 
It is true that the lithium-induced suppression of REM 
time and percent were only minimally significant and 
that neither suppression of REM activity nor prolonga¬ 
tion of REM latency reached the 0.05 confidence level. 
To say now that the increase of REM percent and activity 
and the fore-shortening of REM latency during the post¬ 
drug period are more than could be expected on the 
basis of a withdrawal effect is to assume that the 
magnitude of the post-drug increase must be comparable 
to the magnitude of the drug-induced suppression. This 
assumption is not supported by any available data. 
Thus it would appear that in the case of C.M., unlike 
other patients, there was in fact a rebound from REM 
sleep suppression, beyond what could be expected from 
the clinical change. 
The sleep data of the remaining patients (R.S., 




figures 3-5. It needs only minimal comment. The data 
in the case of R.S. (Tables 11-12, Figure 3) is similar 
to that of M.M., with reference to both stability of 
clinical course and changes of sleep pattern on adminis¬ 
tration and withdrawal of lithium. The greater frequency 
of serum lithium determination, and perhaps the relative 
stability of R.S.'s clinical course as well, allowed one 
to document a positive correlation (R - 0.8078, p^0.02) 
between her serum lithium levels and increases in delta 
sleep time above the mean value for the pre-drug period. 
This correlation was not found in other patients. 
Sleep data in the case of J.E. (Tables 13-1^) is 
similar to that of M.M., except that changes in sleep 
pattern on administration and withdrawal of lithium are 
not as often significant as with M.M. or R.S. Whether 
this reflects the generally lower serum lithium values 
that were found and/or a difference in diagnosis cannot 
be answered from the data. Although intensive psy¬ 
chiatric ratings were not obtained during the period of 
drug administration, the clinical summary of the resi¬ 
dent physician notes progressive improvement and 
"emergence from psychosis" during the hospitalization. 
’ , . 
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There is also a concurrent, and significant, increase 
in time spent asleep, sleep period utilization, and 
number of REM periods, as well as a significant reduc¬ 
tion in early morning awakening. These trends are not 
clearly related to the administration and withdrawal of 
lithium. 
Both remaining cases, L.S. and G.H., were studied 
only during an initial placebo period, followed by a 
drug period. The data thus permits very limited in¬ 
ferences. Despite his having the highest mean lithium 
serum level (1.28 + 0.13, n = 8), L.S.'s sleep pattern 
did not change significantly by most measures with the 
administration of lithium (Tables 15-16, Figure 5). 
Most of the REM and delta sleep parameters changed in 
directions consistent with those shown by other patients, 
but narrowly missed being significant. Only the increase 
in abnormal REM time was significant9 . As seen in 
Figure 5, the pre-drug sleep records were taken while 
the patient was hypomanic, while lithium sleep records 
were taken while the patient was depressed. There is 
not sufficient clinical data to say that the mood switch 





nied by a significant alteration in sleep patterns. If, 
on the other hand, the switch was spontaneous, there is 
not enough base line sleep data on this patient to say 
that the depression was accompanied by changes in sleep 
pattern that would have masked the usual drug-induced 
changes. Indeed, the question of whether lithium- 
induced changes are usually, or always, accompanied by 
specific changes in sleep pattern is answerable only if 
one has extensive base line data showing those sleep 
changes that naturally accompany the patient's mood 
switches. Similarly, to establish that these changes 
in sleep pattern are correlates of mood switches, it 
is necessary to show that the correlation is not altered 
or abolished in drug-induced mood switches. 
The sleep data on patient G.H. (Tables 17, 18) 
shows a splintering of drug effect. While the changes 
in REM sleep patterns are marked and consistent with 
those shown by other patients, delta sleep does not 
increase significantly. This may be an effect of the 
23 
patient's age. In the study by Kupfer et. al., the 
two patients who did not show an increase in delta sleep 




jects. Had drug-period psychiatric ratings on G.H. 
been available, it would have been of direct clinical 
interest to see how, if at all, the lack of delta 
response related to both immediate clinical response 
(if any), or how well it functioned as a prognostic 
sign of lithium's prophylactic value. 
Finally, as shown in Table 19, an attempt was 
made to correlate changes in sleep measures with 
fluctuations in serum lithium values. The limited num¬ 
ber of values in any individual patient necessitated 
the pooling of all patient data. Unavoidably, this 
introduced the effects of a variety of diagnoses and 
clinical courses and thus could have distorted the ob¬ 
servation of serum level-response relationships. An¬ 
other limitation was that serum levels were drawn in 
the morning, eight to twelve hours after the last dose. 
These morning values were then correlated with changes 
shown by records of both the preceding and following 
nights. It would obviously have been better if such 
a time lapse could be eliminated. Despite these limi¬ 
tations, significant corr-elations were found between 
fluctuations in serum lithium levels and changes in 
■ 
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REM latency (both nights) and REM percent (preceding 
night only). These observations seem at variance with 
the data reported for M.M., where phasic REM activity 
was apparently more sensitive to changes in daily dos¬ 
age and serum level than REM time or REM percent. It 
could be that the threshold for drug effect on REM 
activity and intensity is lower and that a serum level- 
response relationship exists within a narrower range of 
serum values than for REM percent. Whatever the rela¬ 
tionship, a correlation coefficient of 0.3 or 0.U means 
that a large portion of the variability in REM latency 
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TABLE 2. -- COMPARISON OF SLEEP PATTERNS BEFORE (l) 
AND DURING (ll) LITHIUM ADMINISTRATION 
51 
Determination I (Placebo) II (Lithium Carbonate) P 
mi nutes 
REM Time 67.4 + 14.0 45.5 + 15.9 0.02 
REM Percent 19.5 + 4.4 12.5 + 4.2 0.001 
# REM Periods 3.7 + 0.5 3.6 + 0.8 NS* 
REM Interval 1-2 84.1 + 18.6 79.6 + 21 .4 NS 
2-3 82.2 + 10.7 81.3 + 14.6 NS 
3-4 72.0 + 15.6 76.7 + 6.1 NS 
REM Period Duration 
#1 14.6 + 4.7 7.4 + 4.0 0.05 
n 15.9 + 2.6 11.9 + 5.8 NS 
n 24.3 + 5.4 15.3 + 3.5 0.005 
#4 20.9 + 5.8 17.3 + 5.5 NS 
Abnormal REM 
% 
Time 1.9+ 2.3 4.9 + 2.4 NS 
REM Latency 70.2 + 23.0 103.9 + 36.4 0.02 
REM Activity 125.2 + 67.0 71.0 + 36.2 0.1 
REM Activity/Net 
S 1 eep 37.3 + 19.6 19.7 + 10.2 0.05 
Delta SIeep 17.1 + 13.4 47.5 + 22.4 0.05 
Delta Percent 6.7 + 4.6 15.8 + 4.7 0.05 
Delta Latency 28.9 +H.4 16.8 + 3.3 NS 
Net Sleep 360.2 + 56.4 365.9 + 36.5 NS 
Sleep Period 
Utilization (%) 83.2 + 10.7 87.2 + 5.9 NS 
Intermittent Wake¬ 
fulness 18.4 + 22.6 17.6 + 19.2 NS 
Early Morning 
Awakening 19.5 + 28.4 11.4 + 13.1 NS 
Sleep Latency 32.4 + 25.8 21.3 + 12.0 NS 
*NS = not significant 

TABLE 3. -- COMPARISON OF SLEEP PATTERNS IN PLACEBO PERIODS 
BEFORE (I) AND AFTER (ill) LITHIUM 
Determination 1 (Before) 1 1 1 (After) P 
REM Time 69-5 + 16.5 
minutes 
98.3 + 18.0 0.1 
REM Percent 21.5 + 4.0 24.4 + 3.9 NS 
# REM Periods 3-5 ± 0.5 4.4 + 0.8 NS 
REM Interval 1-2 89.4 + 21.1 82.9 + 23.7 NS 
2-3 80.0 + 12.9 73.5 + 16.6 NS 
3-4: 63.7 + 2.7 69.4 + 12.1 NS 
REM Period Duration 
16.7 + 3.0 19.3 + 5.4 . NS 
n 17.1 + 2.2 21.6 + 9.8 NS 
#3 26.9 + 4.7 27.5 + 10.6 NS 
#4 21.8 + 7.8 28.4 + 
% 
6.1 NS 
Abnormal REM Time 2.5 + 3.1 2.00+ 1.3 NS 
REM Latency 70.3 + 29.7 55.5 + 7.3 NS 
REM Activity 149.2 + 71.3 184.1 + 62.1 NS 
REM Activity/Net 
Sleep 45.6 + 19.1 45.6 + 18.1 NS 
Delta Sleep 15.2 + 9.1 22.7 + 6.3 NS 
Delta Percent 5.12+ 3.2 5.55+ 1.6 NS 
Delta Latency 30.6 + 12.5 53.4 + 27.0 0.05 
Net Sleep 332.2 + 21.2 413.7 + 40.4 0.05 
Sleep Period 




Wakefulness 21.3 + 27.2 15.7 + 27.9 NS 
Early Morning 
Awakening 20.3 + 35.8 3.42+ 1.0 NS 
Sleep Latency 42.5 + 26.4 26.5 + 19.5 NS 
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TABLE 4. — COMPARISON OF SLEEP PATTERNS BY THIRDS OF NIGHTS 
BEFORE (I) AND DURING (ll) LITHIUM ADMINISTRATION 
Determination ! (Placebo) II (Lithium Carbonate) 
minutes 
REM Time 1 14.7 + 6.2 5.7 + 4.5 0.05 
2 23.5 + 7.0 14.7 + 6.2 0.002 
3 27.7 + 5.6 25.1 + 6.8 NS 
REM Activity 1 23.1 + 16.2 7.4 + 6.1 0.1 
2 43.9 + 23.9 23.4 + 15.2 0.01 
3 55.2 + 30.8 39.9 + 17.3 NS 
REM Activity/Net 
Sleep 1 18.2 + 1 1 .2 5.9 + 4.7 0.05 
2 43.4 + 23.7 19.7 + 11.9 0.02 
3 47.0 + 25.8 34.2 + 18.6 NS 
Delta Sleep 1 12.6 + 10.0 32.5 + 14.1 0.05 
2 4.1 + 3.8 11.2 + 7.7 0.05 
3 0.9 + 1.1 3.9 + 3.5 0.1 
Abnormal REM Time 1 1.2 + 1.8 2.7 + 1.8 NS 
2 0.4 + 0.3 1.0 + 0.6 0.1 
3 0.4 + 0.50 1.0 + 0.7 NS 

TABLE 5. -- COMPARISON OF REM AND DELTA SLEEP 
BY PEARSON I AN CORRELATION 
1 (placebo) II (1 i th i um) III (piacebo) 
















REM Latency vs. 







TABLE 6. — COMPARISON OF SLEEP PATTERNS BY THIRDS OF NIGHTS 
BEFORE (I) AND AFTER (ill) LITHIUM 
Determination I (Before) III (After) P 
REM Time 1 18.2 + 4.3 21.0 + 3.3 NS 
2 24.8 + 10.5 30.0 + 9.4 NS 
3 29.2 + 6.5 41.0 + 5.2 NS 
REM Activity 1 34.2 + 15.8 33.5 + 6.6 NS 
2 57.1 + 29.2 58.7 + 31.9 NS 
3 71.9 + 37.8 86.1 + 36.0 NS 
REM Activity/Net 
S1eep 1 27.6 + 6.0 25.3 + 7.1 NS 
2 61.2 + 19.6 47.4 + 22.5 NS 
3 61.9 + 30.7 65.9 + 33.0 NS 
Delta Sleep 1 14.5 + 5.5 18.1 + 8.7 , NS 
2 4.2 + 1.0 4.5 + 3.1 NS 
3 0.7 + 1.2 1.4 + 1.9 NS 
Abnormal REM Time 1 1.5 + 2.5 1.2 + 0.8 NS 
2 0.5 + 0.2 0.5 + 0.5 NS 
3 0.6 + 0.5 0.6 + 0.5 NS 
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TABLE 9. — COMPARISON OF SLEEP PATTERNS IN PATIENT CM 
• * 
Determination Baseline Lithium Pj Placebo ?2 
REM Time 57.3 + 16.0 37.8 + 11.9 0.05 118.3 + 53.2 0.01 
REM Percent 19.0 + 6.3 11.2 + 2.5 0.05 27.3 + 7.2 0.05 
ft REM Periods 3.0 + 0.5 2.2 + 0.8 0.1 4.2 + 0.4 0.001 
REM Period Duration 
#1 18.1 + 7.3 12.2 + 10.0 NS 26.7 + 5.6 0.05 
n 16.0 + 5.4 21.8 + 14.9 NS 32.1 + 6.7 0.001 
#3 26.2 + 16.3 16.0 + 1.4 NS 37.2 + 14.9 NS 
#4 ... 35.7 + 13.9 
REM Activity 93.0 + 18.9 77.2 + 51.0 NS 192.3 + 22.6 0.001 
RA/TSA 27.1 + 6.4 24.4 + 15.6 NS 42.7 + 4.9 0.002 
REM Latency 113.4 + 43.6 144.0 + 82.5 NS 64.2 + 4.6 0.05 
Delta Sleep 4.0 + 5.1 60.8 + 20.7 0.001 19.5 + 17.8 0.05 
Delta Percent 1.1 4- 1.3 20.2 + 8.2 0.001 4.2 + 4.4 
Delta Latency 28.8 + 10. 1 13.3 + 8.1 0.05 64.6 + 49.7 NS 
Net Sleep 346.8 + 40.6 310.8 + 40.3 NS 466.; 3 + 17.3 0.001 
Sleep Period 92.0 + 3.7 92.9 + 4.8 NS 94.2 + 3.2 NS 
Utilization 
1 ntermittent 1.5 + 1.5 1.0 + 2.2 NS 0.0 0.05 
Wakefulness 
Early Morning 2.3 + 3.5 2.4 + 3.6 NS 3.3 + 7.2 NS 
Awaken i ng 
Sleep Latency 25.1 + 10.4 20.8 + 23.2 NS 29.8 + 22.5 NS 
P| = baseline placebo compared with lithium 
~ predrug (baseline) placebo compared with post-drug placebo 

TABLE 10. — COMPARISON OF SLEEP DATA BY 
THIRDS OF NIGHTS IN PATIENT CM 
Determination Placebo Lithium P 
REM Time 1 8.1 + 9.8 1.4 + 3.1 NS 
2 19.4 + 8.3 11.4 + 9.8 NS 
3 29.8 + 14.7 25.0 + 10.5 NS 
REM Activity 1 11.8 + 15.7 2.0 + 4.5 NS 
2 38.5 + 19.5 29.4 + 31.3 NS 
3 43.8 + 18.8 45.8 + 30.5 NS 
RA/TSA 1 9.7 + 12.9 2.2 + 5.0 NS 
2 33.5 + 17.7 28.2 + 31.5 NS 
3 38.4 + 17.0 42.7 + 23.7 NS 
Delta 1 4.0 + 5.0 45.5 + 18.7 0.001 
2 0.0 7.30 10.9 NS 






























TABLE 11. — COMPARISON OF SLEEP PATTERNS IN PATIENT RS 
BEFORE (I), DURING (ll), AND AFTER (III) LITHIUM 
t 




REM Time 53.3 + 19 6 43.4 + 16.8 75.3 + 18 7 NS 0.05 
REM Percent 17.4 + 3 7 13.1 + 7.0 18.8 + 2 2 NS NS 
# REM Periods 3.2 + 1 2 3.3 + 1.1 4.2 + 1 0 NS NS 
REM Period #1 13.2 + 5 6 10.4 + 4.5 16.8 + 11 0 NS NS 
#2 15.3 + 9 4 9.1 + 5.5 13.9 + 11 1 0.1 NS 
#3 29.2 + 10 3 19.8 + 9.8 15.8 + 12 8 0.1 0. 1 
#4 14.2 + 11 1 15.0 + 10.1 24.1 + 8 9 NS NS 
REM Interval 1-2 106.4 + 29 0 110.2 + 41.3 111.6 + 47 7 NS NS 
2-3 96.4 + 39 2 78. 1 + 41.2 59.3 + 18 4 NS 0. 1 
3-4 66.4 + 12 3 71.7 + 18.6 85.0 + 18 9 NS NS 
REM Activity 87.4 + 47 2 60.6 + 31.4 100.5 + 28 6 NS NS 
RA/TSA 31.9 + 11 5 18.7 + 12.4 24.9 + 4 5 0.05 NS 
REM Latency 59.0 + 10 9 74.0 + 21.3 56.3 + 13 3 0.1 NS 
Abnormal REM Time 1.2 + 1 7 1.8 + 3.0 0.5 + 0 8 NS NS 
Delta Time 18.3 + 15 9 77.0 + 34.5 21.8 + 24 6 0.001 NS 
Delta Percent 7.7 + 7 3 21.6 + 7.1 5.5 + 5 1 0.001 NS 
Delta Latency 48.7 + 57 3 13.5 + 6.0 86.3 + 55 8 NS NS 
Net Sleep 309.1 ±1°7 1 349.4 + 77.7 404.3 + 99 0 NS 0. 1 
Sleep Period Utilization (%) 66.6 + 20 8 75.9 + 12.8 77.7 + 18 4 NS NS 
Intermittent Wakefulness 59.8 + 40 9 52.0 + 42.5 57.6 + 66 4 NS NS 
Early Morning Awakening 3.0 + 2 2 4.2 + 7.1 2.1 + 2 1 NS NS 




= comparison of baseline placebo with lithium 
= comparison of baseline placebo with post-drug placebo 
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TABLE 12. — COMPARISON OF SLEEP PATTERNS BY THIRDS OF NIGHTS 
IN PATIENT RS 
* 
Determination 1 11 1 1 1 P P 
1 2 
REM Time 1 13.3 + 5.1 10.4 + 4.5 21.2 4- 7.3 NS 0.05 
2 15.6 + 9.5 9.9 + 6.0 19.2 4- 12.3 NS NS 
3 25.1 + 6.7 23.1 + 14.0 35.2 4- 5.1 NS 0.01 
REM Activity 1 19.2 + 12.9 13.4 + 8.2 26.2 4- 9.7 NS NS 
2 29.1 + 18.1 12.2 + 8.3 23.0 4- 14.8 0.02 NS 
3 40.2 ✓ 
+ 36.2 34.8 4- 26.1 49.5 4- 21.3 NS NS 
RA/TSA 1 20.8 + 16.4 11.4 4- 9.6 18.3 4- 6.9 NS NS 
2 54.6 4- 81.8 13.4 4- 12.9 23.9 4- 8.4 NS NS 
3 33.0 + 31.1 25.4 + 8.0 34.6 4- 15.1 NS NS 
Delta 1 11.6 4- 13.3 45.2 + 18.5 10.8 4- 8.9 0.001 NS 
2 4.5 + 7.2 23.3 + 20. 1 7.8 4- 13.7 0.02 NS 
3 2.1 4- 4.0 7.6 + 6.6 3.7 4- 5.7 0.05 NS 
Abnormal REM Time 1 0.0 0.3 + 0.7 0.3 + 0.8 NS NS 
2 0.4 + 0.7 0.7 4- 1.3 0.0 NS NS 
3 0.8 + 1.3 0.8 4- 1.4 0.2 4- 0.4 NS NS 
Pj = comparison of baseline placebo (l) with lithium (ll) 
>2 = comparison of baseline placebo (l) with post-drug placebo (III) 
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TABLE 13. — COMPARISON OF SLEEP PATTERNS IN PATIENT JE 
BEFORE (I), DURING (II), AND AFTER (III) LITHIUM 
t 




REM Time 83.3 + 10.2 73.8 + 24.3 104.1 + 21.1 NS NS 
REM Percent 26.0 + 2.6 19.3 + 5.4 24.9 + 4.0 0.1 NS 
#REM Periods 3.7 + 0.6 4.4 + 0.9 5.5 .+ 0.9 NS 0.02 
REM Period #1 15.3 + 20.5 7.1 + 4.4 19.6 + 6.3 NS NS 
til 16.7 + 4.0 13.2 + 7.5 12.6 + 2.9 NS NS 
til 31.5 + 8.0 15.6 + 4.3 21.3 + 4.7 0.002 0.05 
tik 29.8 + 7.4 23.9 -i. 12.3 22.7 + 13.6 NS NS 
REM Interval 1-2 63.5 + 10.6 56.9 + 12.2 63.5 + 9.1 NS NS 
2-3 68.5 + 7.8 64.5 + 10.5 64.2 .+ 9.1 NS NS 
3-4 82.8 + 38.2 56.4 + 16.2 
REM Activity 182.0 + 16.5 132.1 + 47.2 193.0 + 66.0 NS NS 
RA/TSA 56.8 + 5.1 34.2 + 7.9 45.8 + 12.7 0.002 NS 
REM Latency 45.7 + 7.4 59.1 + 21.8 46.4 + 7.2 NS NS 
Abnormal REM Time 6.0 + 7.2 3.3 + 5.9 2.4 + 4.0 NS NS 
Delta Time 25.5 + 19.6 46.3 + 13.0 31.9 + 10.2 0.1 NS 
Delta Percent 7.8 + 5.9 12.6 + 4.1 7.8 + 2.6 NS NS 
Delta Latency 22.8 + 4.6 17.4 + 8.8 33.4 + 16.5 NS NS 
Net Sleep 319.7 + 10.8 381.3 + 83.4 415.7 + 38.3 NS 0.00! 
Sleep Period Utilization (%) 73.0 + 8.7 86.2 + 15.2 94.1 + 2.9 NS 0.00 
Intermittent Wakefulness 2.7 + 4.6 22.0 + 45.5 2.1 + 4.0 NS NS 
Early Morning Awakening 74.0 + 3.6 18.8 + 52.6 4.3 + 6.6 NS 0.00' 
Sleep Latency 42.0 + 53.7 13.6 + 7.1 15.5 + 9.4 NS NS 
■J* 
p^ = comparison of baseline placebo (l) w? th 1 i thiurn (II) 
= comparison of baseline placebo (l) with post-drug placebo (III) 
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TABLE 14. — COMPARISON OF SLEEP PATTERNS BY THIRDS OF NIGHTS 
IN PATIENT JE / 
t 




REM Time i • " 21.7 + 28.9 11.4 + 9.1 24.1 + 7.4 NS NS 
2 36.2 + 6.2 25.3 + 9.7 34.6 + 9.8 NS NS 
3 25.8 + 22.4 36.9 + 15.8 45.2 + 14.6 NS NS 
REM Activity 1 32.7 + 43.6 15.9 + 13.4 35.6 + 15.0 NS NS 
2 87.3 + 16.6 49.5 + 22.7 68.8 + 19.8 0.05 NS 
3 61.7 + 53.4 66.9 + 26.9 87.4 + 41.9 NS NS 
RA/TSA 1 29.5 + 38.7 11.4 + 9.5 25.1 + 9.2 NS NS 
2 83.2 + 13.6 37.4 + 12.4 49.5 + 13.3 0.001 0.005 
3 58.8 + 50.9 63.6 + 37.9 62.6 + 26.5 NS NS 
Delta 1 20.8 + 17.8 36.2 + 10.9 27.8 + 6.8 NS NS 
2 5.0 + 8.7 9.1 + 9.5 4.0 + 5.4 NS NS 
3 0.0 1.63 + 3.8 0.63 + 1.8 NS NS 
Abnormal REM Time 1 4.3 + 5.1 1.6 + 2.8 1.5 2.8 NS NS 
2 0.7 + 1.2 0.9 + 2.5 0.5 + 0.9 NS NS 
3 1.0 + 1.0 0.8 + 2.1 0.9 4- 2.1 NS NS 
compart son 
compart son 
of baseline placebo 
of baseline placebo 
(I) 
(!) 
with lithium (ll) 
with post-drug placebo (ill) 

p~ i t/*r *■/ S, 
Z 
30 0 ^ A/lbuT^0 

TABLE 15. — COMPARISON OF SLEEP PATTERNS IN PATIENT LS BEFORE (l) 
AND DURING (ll) LITHIUM THERAPY 
Determination 1 II P 
REM Time 55.2 + 20.6 44.6 + 13.6 NS 
REM Percent 15.8 + 5.3 11.2 + 3.9 0.1 
# REM Periods 4.0 + 1.2 3.9 + 0.9 NS 
REM Period #1 6.5 + 1.9 8.8 + 6.2 NS 
2 12.6 + 6.8 12.6 + 5.0 NS 
3 19.5 + 13.6 12.7 + 5.0 NS 
4 21.3 + 1.2 13.1 + 5.4 0.05 
REM Interval 1-2 78.6 + 15.6 89.5 + 11.7 NS 
2-3 89.2 + 17.3 88.7 + 13.9 NS 
3-4 99.3 + 30.5 83.7 + 28.8 NS 
REM Activity 66.6 + 23.5 51.9 + 15.9 NS 
RA/TSA 19.6 + 8.3 13.3 + 3.7 0.1 
REM Latency 68.2 + 30.6 110.5 + 51.6 , 0.1 
Abnormal REM Time 0.7 + 1.1 7.40 + 6.0 0.05 
Delta Time 38.2 + 12.8 50.3 + 15.0 NS 
Delta Percent 13.2 + 5.4 15.0 + 4.5 NS 
Delta Latency 22.1 + 8.4 20.4 + 10.3 NS 
Net Sleep 365.3 + 70.2 389.9 + 43.1 NS 
Sleep Period Utilization (%) 89.4 + 5.0 89.3 + 5.4 NS 
Intermittent Wakefulness 1.5 + 2.1 4.8 + 6.4 NS 
Early Morning Awakening 27.5 + 23.5 35.2 + 28.1 NS 
Sleep Latency 10.3 + 7.7 10.1 + 7.9 NS 
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TABLE 16. — COMPARISON OF SLEEP PARAMETERS BY THIRDS OF NIGHTS 
IN PATIENT LS 
Determination Placebo Lithium P 
REM Time 1 6.9 + 5.8 5.8 + 7.1 NS 
2 24.3 + 12.4 17.5 + 10.8 NS 
3 20.0 + 2.4 21.1 + 7.0 NS 
REM Activity 1 6.0 + 5.1 5.9 + 6.9 NS 
2 29.2 + 18.8 18.2 + 11.9 NS 
3 26.2 + 8.4 27.5 + 10.2 NS 
RA/TSA 1 4.9 + 4.5 4.3 + 5.2 NS 
2 26.4 + 18.1 13.3 + 8.1 NS 
3 24.0 + 11.5 21.0 + 7.3 NS 
Abnormal REM Time 1 0.1 + 0.2 4.0 + 3.5 0.05 
2 0.6 + 0.9 1.3 + 1.5 NS 
3 0.0 1.8 + 3.3 NS 
Delta 1 27.4 + 9.6 27.7 + 16.8 NS 
2 10.9 + 12.2 17.6 + 10.2 NS 
3 2.3 + 3.3 4.6 + 8.7 NS 
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TABLE 17. — COMPARISON OF SLEEP PARAMETERS IN PATIENT GH 
BEFORE AND DURING LITHIUM TREATMENT 
Determination Placebo Lithium P 
REM Time 70.8 + 17.4 25.5 + 19.5 0.001 
REM Percent 15.2 + 4.3 6.6 + 3.5 0.005 
# REM Periods 4.2 + 0.4 4.3 + 2.1 NS 
REM Period #1 14.5 + 10.6 1.0 + 1.2 0.005 
2 14.3 + 8.4 4.4 + 6.9 0.05 
3 18.7 + 5.5 10.0 + 9.8 0.1 
4 17.7 + 8.3 12.0 + 11.3 NS 
REM Interval 1-2 68.3 + 25.3 68.3 + 40.4 NS 
2-3 83.7 + 11.0 106.5 + 17.8 0.05 
3-4 69.7 + 14.4 71.4 + 29.5 NS 
REM Activity 88.2 + 43.8 23.9 + 16.5 0.005 
RA/TSA 21.8 + 8.4 4.3 + 3.3 0.001 
REM Latency 71.8 + 20.5 146.9 + 70.5 0.05 
Abnormal REM Time 1.2 + 2.9 5.1 + 5.1 NS 
Delta Time 3.3 + 8.2 10.0 + 26.3 NS 
Net Sleep 466.9 + 31.9 414.0 + 100.6 NS 
Sleep Period Utilization (%) 90.7 + 6.0 89.5 + 13.5 NS 
Intermittent Wakefulness 23.6 + 13.5 21.5 + 42.4 NS 
Early Morning Awakening 7.9 + 16.3 5.1 + 13.3 NS 
Sleep Latency 13.8 + 10.7 11.9 9.2 NS 

TABLE 18 . — COMPARISON OF SLEEP PATTERNS BY THIRDS 
OF NIGHTS IN PATIENT GH 
Determi riat i on Placebo Lithium P 
REM Time 1 18.8 + 7.4 0.6 + 0.8 0.001 
2 22.8 + 6.4 8.5 + 3.9 0.001 
3 29.2 + 16.0 17.1 + 10.7 
REM Activity 1 18.0 + 10.4 0.5 + 0.8 0.001 
2 24.5 + 11.0 6.5 + 7.7 0.005 
3 45.7 + 33.7 17.4 + 12.9 0.1 
RA/TSA 1 12.2 + 7.1 0.3 + 0.4 0.001 
2 16.8 + 10.0 4.3 + 4.6 0.01 
3 33.5 + 28.9 11.9 + 8.1 0.1 
Abnormal REM Time 1 1.2 + 2.9 2.9 + 4.5 NS 
2 0.0 0.37 + 0.7 NS 
3 0.0 1.6 + 3.3 NS 
Delta 1 1.0 + 2.4 7.5 + 19.6 NS 
2 1.3 + 3.3 2.6 + 7.4 NS 
3 1.0 + 2.4 0.1 + 0.3 NS 
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TABLE 19. CORRELATIONS BETWEEN CHANGES IN SLEEP MEASURES 
(FROM MEAN VALUES DURING PLACEBO PERIOD) 
AND ABSOLUTE SERUM LITHIUM LEVELS 
A. — CORRELATION WITH LEVELS DRAWN 
BEFORE RECORD 
ON A.M. 
Determination Pearson Coefficient DF P 
REM Percent -0.4439 37 0.01 
REM Actlvity -0.1993 37 NS 
RA/TSA -0.1652 36 NS 
REM Latency +0.3457 37 0.05 
Delta Percent +0.1448 37 NS 
B. — CORRELATION WITH LEVELS DRAWN 
AFTER RECORD 
ON AM 
Determination Pearson Coefficient DF P 
REM Percent -0.18 25 NS 
REM Activity -0.1968 25 NS 
REM Latency +0.4993 25 0.01 




Most of the observations reported by Kupfer 
et, al»2^ have been replicated closely in this study. 
Serum lithium carbonate levels of 0.8 mEq/liter or 
greater are associated with a significant inhibition 
of REM sleep in both manic and depressed patients. 
This association is most clearly seen in the reduc¬ 
tions of REM sleep percent and phasic REM activity 
per minute of net sleep. The concept of drug effect 
is supported by a return of REM sleep measures, such 
as percent, activity, and latency, to pre-drug levels 
after discontinuation of lithium. A second corrobo¬ 
rative observation is that REM sleep latency is found 
to have a significantly positive correlation with 
serum lithium levels, both during the night before 
and the night after these levels are drawn. It is 
somewhat surprising that a similar correlation has 
not been found for REM activity. In the case of M.M., 
suppression of REM activity varied directly with 
moderate and high dosage, whereas a high dosage was 
required to suppress REM sleep time. This finding 
may mean only that the tonic and phasic components 
j, i - r . .u 
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of REM sleep have different thresholds for suppression 
by lithium. Variation with dosage may occur only with¬ 
in a small range of serum levels. The question could 
be answered if serum levels were drawn before sleep 
and long enough after the last dose to avoid a falsely 
high value (due to post-absorptive peak). A large num¬ 
ber of samples would also be required. 
It has been shown that the inhibition of REM sleep 
associated with lithium carbonate administration occurs 
mainly during the first and second thirds of the night. 
This could be related to the observation of Schou-3 
that post-absorptive serum peaks occur two to four 
hours after the last dose. Since the last daily dose 
in this study was administered at 9 p.m,, the post- 
absorptive peak would be reached between 11 p.m. and 
1 a.m., or during the first third of the night. Assum¬ 
ing that lithium levels in brain peak somewhat later, 
one might expect maximum suppression to occur during 
the second third of the night. This was in fact ob¬ 
served. If lithium were given at the time of sleep, 
rather than two hours before, one might see maximum 





of the night. 
fCg/A„ 
The distribution of abnormal, or atypicalAsleep 
also follows the same pattern, with maximal increases 
during the first and, particularly, the second third 
of the night. Most of the abnormality is character¬ 
ized by a random admixture of beta activity (sleep 
spindles) with the usual EEG and EOG of REM sleep. 
Rarely there is an admixture of delta frequencies with 
the REM-type EEG. In addition, most of the atypical 
REM sleep is characterized by low levels of REM activ¬ 
ity, suggesting that it may be a lithium effect. Upon 
discontinuation of the drug, the amount of atypical 
REM sleep returns to pre-drug levels. They physio¬ 
logic meaning of atypical REM sleep is not clear. 
It seems to be associated with the administration of 
lithium, although increases during the drug period 
were significant (p 0.05, patient L.S.) in only one 
patient. It is tempting to speculate that it may 
represent an escape phenomenon or reversal of REM 
suppression. In this regard, most of the atypical 
REM sleep seemed to occur at the beginning of REM 
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period was under way. 
The increase in delta sleep reported by Kupfer 
has also been found in this study. Interestingly, 
the increase in delta percent is significantly cor¬ 
related with the decrease in REM percent during the 
drug period. There is no such correlation in either 
period before or after the drug period. The question 
raised is whether lithium actively drives the bio¬ 
chemical events that produce delta sleep, or indi¬ 
rectly permits the increase perhaps by actively sup¬ 
pressing REM sleep. Three of our observations are 
pertinent to the question. (l) A reduction in delta 
sleep latency associated with the administration of 
lithium and abolished by its discontinuation would 
be consistent with the idea of a direct, driving 
effect. A significant reduction was in fact noted 
in the case of C.M., the patient who showed the most 
pronounced increase in delta percent while on lithium. 
While a reduction was also noted in all other pa¬ 
tients, it failed to reach significant levels in any 
of them. (2) The idea of a direct, driving effect on 






correlation between delta latency and REM latency 
could be found during the drug period. In fact, 
however, no such correlation was found in any of the 
patients individually or as a group. (3) While 
changes in REM latency correlated positively with 
fluctuations in serum lithium values, changes in 
delta latency did not. Taken together, these three 
observations are more consistent with the idea of an 
indirect, permissive effect than with a direct, 
driving effect. The evidence is at best equivocal, 
however. 
One of the more intriguing questions in bio¬ 
logic psychiatry is whether the sleep changes associ¬ 
ated with lithium administration reflect the drug's 
mechanism of action as a mood normalizer. There are 
a number of psychopharmacologic observations pertin¬ 
ent to the issue of whether the biochemical basis 
for the therapeutic effects of lithium is related to 
its inhibition of REM sleep, its increase of slow- 
wave sleep, and its lack of sedative effect. 
Various classes of anti-depressant medications 




period. These include not only lithium salts (direct 
serum level-response relationship), but also tricyclic 
agents^ and MAO inhibitors,^ Also, while both in¬ 
creases and decreases in REM sleep have been reported 
in depressed patients, a foreshortening of REM latency 
has been a consistent finding,^ The inference 
from these two observations is clear. If the mechan¬ 
ism of action of the anti-depressants is reflected in 
the changes of REM latency, then favorable clinical 
response should be associated with a return of REM 
latency to normal or greater than normal ranges. 
This association has been reported by Kupfer and 
Foster,cij One question now arising is whether lithium- 
and MAOI-responsive depressions show improvement only 
at the point of complete REM-sleep suppression—a 
position taken by Oswald (unpublished data presented 
at the APSS meeting in Bruges, 1971) but lacking con¬ 
firmation to date. Wyatt et, al,4^ have observed 
marked improvement in the depressive symptoms of six 
patients during a period of MAOI-induced REM-sleep 
suppression. After MAOI discontinuation, two of 








compensation. While this observation does not estab¬ 
lish that REM-sleep deprivation itself is responsible 
for clinical changes, it does provide further pre¬ 
sumptive evidence for an association, or coincidence, 
between clinical improvement and inhibition of REM 
sleep. 
It now becomes problematic, however, to relate 
the anti-manic effects of lithium to the prolongation 
of REM latency also observed in the sleep records of 
manic patients. The drug effect is observed despite 
already prolonged REM latencies in the untreated sleep 
of these patients. A similar quandary can be formu¬ 
lated with regard to the drug-induced increase in 
delta sleep, since it appears that in both mania and 
depression an increase in delta sleep is significantly 
associated with a prolongation of REM latency and de¬ 
crease of REM percent. One issue raised by this 
apparent quandary is whether in fact pharmacologic 
inhibition of REM sleep is identical to the natural 
condition of REM deprivation observed in manic states. 
In a recent study, "The Switch Process in Manic- 
depressive Illness," Eunney et. al.1 report that net 
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sleep and REM time decrease just prior to and during 
the manic episode. They hypothesize that in man a 
decrease in REM sleep is associated with an increase 
in central catecholamine levels and/or a decrease in 
indoleamines, while the opposite changes are associ¬ 
ated with an increase in REM sleep. 
Bunney et, al. then try to conceptualize the 
anti-manic effects of lithium in terms of this formu' 
lation of the catecholamine hypothesis. Lithium may 
exert anti-manic effects by decreasing the amount of 
catecholamines available at central adenergic recep¬ 
tors in brain. They cite several observations in 
support, (l) In animal studies, lithium has been 
shown to decrease the release of norepinephrine and 
serotonin from brain stem slices, to increase intra- 
neuronally-derived deaminated metabolites of cate¬ 
cholamines, and to increase the uptake of amines in 
synaptosomes. (2) Blood platelets from patients 
treated with lithium also show an increased uptake 
of catecholamines, whereas imipramine has the oppo¬ 
site effect. 
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effects of lithium on the sleep of both manic and de¬ 
pressed patients to Bunney's formulation of its mecha¬ 
nism of action as a mood normalizer. One would have 
predicted an increase in REM sleep if lithium works 
by reducing the amount of catecholamines available 
centrally in manic patients. Instead, a significant 
decrease has been found in mania and depression alike. 
If one postulates that REM sleep is primarily a func¬ 
tion of serotonin-mediated events, and that lithium- 
induced suppression of REM sleep may reflect a de¬ 
crease in the amount of serotonin available centrally, 
then the problem becomes that of relating the switch 
process to serotonin metabolism. Indeed, if lithium's 
therapeutic effectiveness in mania is due to its de¬ 
creasing the amount of functional catecholamines, it 
is also difficult to rationalize its effectiveness 
(largely prophylactic) in depression, which is theo¬ 
retically associated with already decreased levels of 
adrenergic activity. Perhaps as Bunney suggests, one 
may be forced to hypothesize an "underlying dysfunc¬ 
tion" in bipolar illness that may not be related 
causally to catechol- and indoleamine function. The 
.doiq 
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similar effects of lithium on the sleep of both manic 
and depressed patients may parallel its alteration of 




LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXSIS : 
A CRITICAL REVIEW OF METHODOLOGICAL ISSUES 
In the literature on lithium in psychiatric thera¬ 
py and prophylaxsis, there is some evidence that it 
specifically counteracts manic-depressive mood swings 
without apparently affecting normal mental function. 
Studies of the drug's specific therapeutic activity 
against mania do provide clearcut evidence, but even 
these studies are beset by a number of problems. Other¬ 
wise, the nosological specificity of lithium is less 
clear. The exact limits of its usefulness in the thera¬ 
py and prophylaxsis of recurrent mania and/or depression 
have yet to be defined. 
Gershon writes that there are well over fifty pub¬ 
lished reports on the use of lithium in psychiatric 
I O 
disorders. A composite of these studies shows an 
"improvement” rate of 60 to 100 per cent in mania 
treated with lithium. Thus, for example. Rice found 
that only 3 out of 37 patients failed to respond to 
lithium,Belling, 8 of 32,and Hartigan, 6 of 20 




controlled, study, Wharton and Fieve found that only 
8 of 25 patients who had been refractory to phenothia- 
zines did not respond favorably to lithium. 
There is a large difference, however, between im¬ 
provement rates reported in these open studies, and 
those reported in double-blind, controlled studies. In 
the latter, only 30 to Uo per cent of patients had an 
unequivocally favorable response to lithium. This dif¬ 
ference underscores the danger of observer enthusiasm in 
psychiatric studies, and hence the need to attempt con¬ 
trolled, double-blind investigation. In fact, there is 
a dearth of well-controlled studies in the clinical 
literature. Five studies are historically important, 
both because their claims are among the better founded 
and because they exemplify well the problems of mean¬ 
ingful assessment of drug effect. These studies merit 
critical review, not because of doubt of the thera¬ 
peutic and prophylactic potentialities of lithium, but 
because the drug is not likely to be used to maximum 
advantage without the kinds of trials required for the 
establishment of efficacy. 
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In 195*1, Mogens Schou et. al.^ published the first 
controlled study of lithium treatment in mania. Thirty- 
eight manic patients (21 females, 17 males) were studied: 
thirty "typical" cases ("pure" manias, with delusions in 
accordance with,and probably secondary to, the patient's 
mood, easy contact with the patient, and no, or incon¬ 
spicuous, hallucinations), and eight "atypical" cases 
(delusions without overt relation to mood, hallucinations 
of more than episodic character, and periods with reti¬ 
cence and contact difficulties, despite the frequent 
appearance of the "pure" manic phase in these patients). 
Daily clinical assessment of emotional level and motor 
activity was made on the basis of a three-point global 
impression of severity. Lithium was given both in open 
treatment and using a "blind" scheme, where patients re¬ 
ceived lithium or placebo for a period, usually two 
weeks, with neither patient nor observer knowing the 
treatment schedule. Medication was shifted "in a random 
manner" every two weeks, from drug to placebo and vice 
versa, as well as from drug to drug and placebo to 
placebo. There were no dietary or salt restrictions; 
extra medications and ECT were avoided whenever possible. 
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Dosage was 2k to 48 mhq of lithium daily (i.e., 900 to 
l800 mg.), administered variously as the chloride, car¬ 
bonate, and citrate salts. The overall psychiatric 
effect was as follows: 
effect:_positive possible negative 
typical patients 12 15 3 
atypical patients 2_3_2 
The placebo data are presented in a different form, and 
no direct overall comparison with the drug data is 
possible. 
Schou elaborates four criteria for "positive" drug 
effect. First, treatment must be able to prevent manic 
attacks occurring at regular intervals (2 patients). 
Second, in patients with constantly elevated emotional 
and/or motor levels, the degree of mania must decrease 
during periods of lithium administration and rebound 
during placebo periods (3 patients). Third, in mania 
that changes rapidly and irregularly in intensity be¬ 
fore treatment, the drug therapy must be accompanied by 
a neutral period significantly longer that the patient's 
spontaneous neutral phases (l patient). Finally, drug 
therapy must bring about a significant shortening of 

the manic phase in patients with previous attacks of 
very regular duration (l patient). Among those l4 
patients who showed a positive effect, eleven were 
females. This may have been related to the generally 
higher serum lithium levels reached in female patients 
(no t-test). Some of these patients also had short 
case histories. However, most cases with short histo¬ 
ries were classified under "possible effect"--whether 
they showed either distinct improvement or improvement 
was less clear cut, since in these patients the spon¬ 
taneous or untreated course of the disease was diffi¬ 
cult to ascertain. Fourteen of 18 patients in the 
"possible-effect" group had short case histories; the 
four remaining patients were considered to have had a 
treatment period insufficient to warrant a positive 
claim. 
Of the five patients who showed no effect, it is 
interesting that two were "atypical" manic-depressives. 
The difference in treatment outcome raises the possi¬ 
bility that these patients were diagnostically dis¬ 
tinctive— assuming, that is, a drug specificity 




the studies described below, in which the response to 
lithium among schizoaffective patients was quite differ¬ 
ent from that of manic patients. The other non-respond¬ 
ers in Schou's study included one patient who showed no 
improvement despite high serum lithium levels, but who 
did respond transiently to electroconvulsive therapy. 
In a second non-responder (clinically "typical"), 
lithium levels never exceeded 0.8 rnEq/L; a third failed 
to respond despite high blood levels on a schedule of 
2^00 mg QD. 
While pioneering in its design, Schou's study has 
a number of methodological problems. He himself ac¬ 
knowledges that reproducible, quantitative assessment of 
the degree of psychosis is often difficult, if not im¬ 
possible. Although evaluations of emotional level and 
motor activity were made daily, no details regarding the 
statistical method used in determining their significance 
was presented. It is questionable whether the global 
assessment of individual attacks, using grades of illness 
or points on a scale, will permit statistical comparison. 
Whether any other method of rating psychiatric symptoms 




impressions is also debatable. Probably, however, the 
use of a rating scale with itemization of symptoms de¬ 
tailed enough to permit a numerical indexing of differ¬ 
entiated changes in mania (for example, a settling of 
behavior, but persistence of grossly abnormal thought 
content), would be of greater value in extended studies. 
This is more likely to be the case when the patient is 
observed through several episodes by the same physician. 
In addition to the lack of a specific psychiatric 
rating device, there is a second difficulty with Schou's 
study. As Ronald Maggs has pointed out,^7 Schou's find¬ 
ings are based in large measure upon retrospective 
appraisal of the variations in intensity and duration 
of patients' preceding manic attacks. This is true of 
all four criteria of positive drug effect. Retrospective 
appraisal is problematic, because it must often depend 
on patient and family recall. It may also be problem¬ 
atic if there is no control of inter- and intra¬ 
observer variability, or of experimental error, in 
assessing onset, duration, and intensity of manic epi¬ 
sodes. Again, both of these difficulties could proba¬ 




psychiatric rating scales. 
A third problem arises in the sequences of change 
of medication described. It is not clear from Schou's 
description that a random allocation of medication has 
been followed. It appears that more than half of the 
sequences followed may have been from nothing or placebo 
to lithium. This ratio could have created a bias in 
favor of manic attacks of short duration. Schou himself 
points out that "most psychoses, and notably manias and 
depressions, show spontaneous variation in duration and 
intensity," so that it is not always evident whether the 
improvement is spontaneous or is drug induced. While 
Schou’s category of "possible effect" reflected this 
contingency, it is not clear that his experimental de¬ 
sign in general did. 
The second attempt at a controlled, double-blind 
assessment of lithium against placebo was published by 
PT 
Maggs in 1963. Twenty-eight manic patients 
(11 M, IT F) were assigned randomly to one of two 
sequences of medication. Each group underwent three 
fourteen-day trial periods: either lithium-rest-placebo, 
or placebo-lithium-rest. A fixed dose of lithium was 
. 
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given, 500 mg. p.o.t.i.d. The placebo was matched with 
the lithium compound for smell, taste, appearance, and 
volume. The patient's clinical state was assessed ini- 
tially and at weekly intervals throughout the trial, 
by a personal interview and by nurses' ratings. Psy¬ 
chiatric evaluations were made with the use of the 
Wittenborn scale. While "atypical" cases were excluded 
from the study, particularly those in whom there was 
evidence of schizophrenia, some symptom complexes were 
common to both cluster III (mania) and cluster V (schizo¬ 
phrenia) of the Wittenborn scale. These included rate 
of change of ideas, motor activity, disrupting routines, 
loud shouting, singing, initiating physical assaults, 
and mood changes. Only relevant symptom complexes in 
cluster V were used as criteria of therapeutic effective¬ 
ness in mania. 
Of Magg's 28 patients, only 18 completed the study. 
Two dropped out because of toxicity; two left against 
medical advice, and five "became so disturbed in behavior 
as to be beyond management." A statistical comparison 
of mean ratings in clusters III and V showed that the 
degree of mania decreased significantly during the second 
, . • . • . 
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week of lithium treatment as compared with the effect 
of placebo on the other group of patients at the same 
time (p ^ 0.05). The degree of schizophrenic excite¬ 
ment also diminished significantly (p £ 0.02). The 
same level of significance was obtained whether lithium 
or placebo was administered first. In addition, a rank- 
order correlation between the clinical ratings of manic 
states and serum lithium levels was made after both one 
and two weeks' treatment, but no significant correlation 
was found. 
One issue to be raised with Magg' statistical treat¬ 
ment is that exclusion of the dropouts may have biased 
results in favor of lithium. Even though nine patients 
were unable to complete the six weeks of treatment, 
analysis of the ratings that were obtained on them might 
have permitted a more realistic assessment than that 
afforded by observing only those patients with more 
faithful attendance and compliance. 
Perhaps the more important issue to be raised with 
this study concerns the quality of experimental control. 
As argued by Grof et. al.controlled therapeutic and 




They may involve two or more patient groups where the 
disease course is followed concurrently in comparable 
groups of patients. One group is treated with the 
therapeutic or prophylactic agent in question, while 
patients in the other group(s) are given a placebo or 
other drugs. This was the design of Magg's study. 
Alternatively, studies may involve only one group of 
patients, in which the disease course is followed in 
the same patients during one or more control periods, 
and one or more therapeutic and/or prophylactic 
periods. In the first design, simultaneous comparison 
of drug and placebo effects depends upon the compara¬ 
bility of the two patient groups. Unless the samples 
are very large, random selection of patients to the 
groups does not ensure such comparability. Although 
the initial mean ratings of psychosis in the two groups 
of Maggs' study were similar, one does not know that 
the groups were otherwise matched for factors known to 
influence the course of recurrent affective disorders. 
These factors include present age and age at first 
episode; number, duration and length of previous epi¬ 




as Maggs', one would have to know that these other vari¬ 
ables had been well controlled, before accepting the 
drug-placebo comparison as completely valid. Knowing, 
furthermore, that the level of significance reported in 
this study was minimal (p ^ 0.05), this objection is 
especially pertinent. 
Evaluation of drug efficacy in small numbers of 
patients might be better pursued with the second schema. 
By using several brief periods of drug withdrawal and 
administration, one should be able to make valid, al¬ 
though limited, statements about drug effect. With pa¬ 
tients acting as their own controls, the issue of com¬ 
parability is removed. The main issue becomes that of 
the quantitative prediction of the course of the dis¬ 
ease. To be sure, the old issue remains—that of 
arriving at a valid estimation of drug efficacy in the 
face of an illness so often characterized by spontaneous 
change. By comparing different control periods in the 
same patients, as well as different drug periods, drug- 
induced changes in clinical parameters, as opposed to 
spontaneous changes, can be more reliably estimated. 
The variability among patients has been eliminated as a 

A13 
factor that might distort drug-placebo comparisons. 
"A Behavioral-Biochemical Study of Lithium Treat¬ 
ment," by William E. Bunney, et. al,, illustrated this 
argument particularly well.0 Bunney reports a longi¬ 
tudinal, double-blind study of two manic patients 
treated in random fashion with lithium carbonate and 
placebo. Detailed daily ratings of mania were recorded 
independently by a psychiatric nursing team and by a 
psychiatrist; both observers were unaware of the pa¬ 
tients' medication schedule or serum lithium level. 
Bunney reports a high degree of correlation between 
psychiatric ratings of mania and nurses' ratings 
(N=8l, r= +0.89, p ^ 0.001). Also, in contrast to Maggs' 
findings, there is a significant correlation between 
changes in mania ratings and changes in serum lithium 
levels (N=89, r= -0.U4, and p <^0.00l). This correla¬ 
tion probably would not have been found without the use 
of detailed daily ratings, in contrast to Maggs' use of 
weekly ratings. The central finding of Bunney's study 
was "a consistent pattern of increased manic symptoms 
within 2h hours of lithium withdrawal in both the manic 
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patients on whom intensive daily evaluations were made." 
In contrast, the first signs of a decrease in mania 
occurred at varying intervals after reinstitution of 
lithium, ranging from one to four days. The design of 
Bunney's study answers much more readily than Maggs' 
the question of whether lithium is needed at thera¬ 
peutic levels at a given time, by using multiple brief 
control and drug periods. 
A fourth controlled study by Johnson et. al.^ 
compared lithium with chlorpromazine in the treatment 
of manic states in 27 patients. A control group of 
lU schizoaffective patients with psychomotor excita¬ 
tion and elation was included to assess lithium's 
therapeutic effect in non-manic situations. The latter 
were in all cases characterized by association with 
"formal thought disorder, inappropriate behavior, 
incongruity of affect and ideation, and systematized 
delusions and hallucinations of more than transient 
nature." Clinical assessment was done on admission 
and at weekly intervals, using the Brief Psychiatric 
Rating Scale, the Treatment Response Assessment Method, 
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and the Wittenborn Scale. Patients were assigned ran¬ 
domly to either drug, both of which were dispensed in 
identical capsules (lithium in 250 mg, or chlorproma- 
zine in 50-100 mg). Dosage was increased until a thera¬ 
peutic response occurred or toxic symptoms were manifest. 
The mean duration of active medication was three to four 
weeks. Maintenance doses of lithium averages 1500-2000 
mg QD, and maintenance doses of chlorpromazine, 
200-1800 mg QD. 
Of 18 manic patients treated with lithium, 1^+ (73%) 
reportedly showed a complete or nearly complete remission 
after a mean treatment of eight days (range: 2-lU days). 
In one case there was remission after two or three days, 
and the possibility of spontaneous abatement could not 
be excluded. One patient showed only "partial remission," 
with unreported serum lithium levels. Another was only 
minimally improved (maximum serum lithium level was 
1.05 mEq/liter: ? taking all medication), and a third 
had showed no improvement at all when the medication was 
discontinued due to diarrhea (serum lithium level was 




shoved, complete or nearly complete remission with chlor¬ 
promazine. Johnson notes that, whereas both drugs pro¬ 
duced a decrease in motor activity, it occurred earlier 
with chlorpromazine. In the same patients, "normaliza¬ 
tion of affect and ideation was consistently obtained 
with lithium carbonate and maintained at optimum dose 
levels with no significant side effects." However with 
the phenothiazine, "return of affect and ideation to 
normal was less clear, less consistent, and slower in 
onset." Interestingly, six of the seven control (i.e., 
schizoaffective) patients on lithium reportedly worsened. 
Lithium therapy was "associated in five cases with signs 
of early organic brain syndrome (disorientation, re¬ 
duced comprehension, and lability of mood)... These 
toxic confusional changes seem similar to the changes 
observed in severe lithium poisoning, with blood levels 
of 3-^ mEq/liter, However, in these patients, blood 
levels ranged from l.lb to 1.97 mEq/liter. A similar 
disturbance was seen in only one manic patient, and 
blood levels rose quickly to 2.25 mEq/liter.’' Their 
final observation was that chlorpromazine produced 
qualitatively similar results in manic and non-manic 
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cases, suggesting "that its tranquilizing effect is non¬ 
specific." No quantitative comparisons of phenothia- 
zine effect on the two groups of patients was presented, 
however. 
At least two interesting suggestions emerge from 
Johnson's study. The first is that lithium, in con¬ 
trast to chlorpromazine, may be specifically effective 
in controlling manic excitement, without exhibiting a 
significant degree of sedative activity. It suggests 
that lithium specifically affects the disease entity 
rather than merely alleviating symptomatic manifesta¬ 
tions. The case would be much stronger if, in addition, 
prophylactic claims could be substantiated. That is, if 
lithium were also effective against cases of recurrent 
depression, as well as against manic states, then one 
might claim that the drug occupies a unique position 
among psychotropic agents, by virtue of its activity 
against both the polar manifestations of manic-depres¬ 
sive psychosis. 
The second suggestion is a corollary of the first 
and deals with the problem of diagnostic specificity. 
As noted earlier, Schou's "atypical" subgroup of manic 
, 
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patients may have been diagnostically different, as 
judged by the difference in treatment outcome of the 
two groups.^ This is supported by Johnson's finding 
of a grossly different response to lithium among the 
schizoaffective patients, as compared to the response 
among manic patients. Whether the toxic response 
pattern described by Johnson is specific to schizo¬ 
affective patients is still not clear. 
19 
In a later, similarly designed study, Johnson 
et. al. again found a "transient, toxic, confusional 
state" accompanying lithium administration in a number 
of schizoaffective patients, "although maximum dosage 
and serum levels attained were no greater than in the 
manic group." They speculate that "the seemingly in¬ 
creased susceptibility to neurotoxicity in this group 
may...be related to suggested differences in lithium 
retention and excretion (Trantner et, al,, Med, J. Aust. 
2:280-91, 1959; Greenspan et. al., Am. J. Psychiat. 
125:512-19, 1988), with a continued lithium retention 
in this group; or to differences in concentration or 
activity at bioreceptors; or to an increased incidence 
of pre-existing neurological damage in this group of 
. . . ' 
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patients (Rochford, Detre, Tucker, Harrow, Arch. Gen. 
Psycniat. 22:llU-19, 1970)." The authors also note a 
similar deterioration in two of their own manic pa¬ 
tients following relapse and readmission. Both had 
responded to lithium treatment initially and had been 
maintained on lithium for six to twelve months. In an¬ 
other study,^ Spring and associates report a similar 
occurrence in three manic patients. 
It is possible that chronic loading in some manic 
patients may alter significantly the response to further 
acute loading, in contrast to the earlier, increased 
susceptibility to toxicity in schizoaffective patients. 
The issue raised is an important one. It concerns the 
possibility of describing major psychiatric syndromes 
in terms of responses to a psychotropic agent. Responses 
might be differentiated by detailed clinical ratings 
and/or measures of psychobiologic parameters, such as 
changes in EEG sleep patterns. The possibility of 
diagnostic specificity in response to a given psycho¬ 
tropic agent may have prognostic implications as well. 
18 
Johnson's results could have been more meaningful 
than clinical impression, had a statistical analysis 
. 
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been presented. A comparison of mean improvement rates 
of symptoms or signs in each group might have provided 
a more exact picture of the specific or non-specific 
effects of each drug. Such scales might include gran¬ 
diosity, accelerated motor activity, distractability, 
flight of ideas, expansiveness, euphoria, pressured 
speech, and sleep disturbance as measured by the various 
i 19 
electroencephalographic parameters. In the 71 study, 
Johnson et. al. did report analyses of specific scores 
on the Brief Psychiatric Rating Scale (BPRS). Using 
the latter, both lithium and chlorpromazine treatment 
produced statistically significant effects in the group 
of manic-depressive patients: t=5.3^ (p <^0.0l) and 
t=6.90 (p 0.01), respectively. Further, the schizo¬ 
affective patients treated with lithium did not show 
significant improvement (t=l.lU9), whereas with chlor¬ 
promazine, a significant improvement was noted (t=U.Ul3, 
p £ 0 .02). On further analysis, only one of the scales— 
Mannerisms—showed a statistically significant advantage 
for lithium in the treatment of manic patients, but all 
of the 18 scales of the BPRS, as well as the total rat¬ 




treated with lithium than for those treated with chlor¬ 
promazine. In contrast, schizoaffective patients 
treated with chlorpromazine showed greater improve¬ 
ment than those treated with lithium on nine of the 
eighteen scales. On only one of these—Tension— was 
there a statistically significant advantage (p 0.05), 
whereas the scale's "blunted affect" gave a statistical 
advantage to lithium. 
Spring et. al»^^ later published another double¬ 
blind comparison of lithium and chlorpromazine in the 
treatment of mania. Their results suggest that sleep 
disturbance and grandiosity show the greatest improve¬ 
ment, and practically equal improvement, with both 
drugs. Other symptoms, such as euphoria, motor hyper¬ 
activity, and pressured speech, reportedly show a much 
greater response to lithium carbonate than to chlor¬ 
promazine. Unfortunately it is not clear how Spring's 
figures representing the improvement rate for specific 
symptoms in each group were derived. Whether the figures 
represent the percent of patients in a group showing any 
improvement in a certain category, or represent mean 
improvement in that category for all persons in the drug 
. 
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group, is not evident. If the latter is the case, it 
is not stated how numerical indices of improvement were 
derived from the global rating scale used for each of 
the target symptoms. The authors claim that, despite 
their strong clinical impression of lithium's super¬ 
iority to chlorpromazine in the treatment of mania, a 
t-test showed no significant difference between the 
two drug groups. Again, however, it is not evident 
what values were used for their comparison, nor how 
they were derived. 
Despite a number of methodological problems, the 
claims for lithium's efficacy in treating mania are the 
best established of any. Less well substantiated are 
claims for its prophylactic effect against manic and 
depressive relapses. The methodological problems in¬ 
volved in prophylactic studies are of considerable 
magnitude. The importance of the studies is also con¬ 
siderable, since, if lithium were without prophylactic 
action, it would clearly be in the interest of patients 
with recurrent affective illness to avoid the needless, 
chronic ingestion of a potentially hazardous substance. 




evidence of a prophylactic action, then it would be in 
the interest of these patients to know how long they 
need remain on the drug. Only trials in which treatment 
has been discontinued after varying periods, and the 
subsequent course of the disease recorded, could begin 
to provide an answer to this question. This problem 
illustrates one of the practical difficulties involved 
in prophylactic trials-—that of the relatively longer 
time required than for therapeutic trials. 
The first systematic and detailed study on lithium 
prophylaxsis was published by P. C. Baastrup and M. Schou 
in 1967.” Eighty-eight patients were selected on the 
basis of two criteria: (l) they had experienced two or 
more manic-depressive episodes during one year, or one 
or more episodes per year during at least two years, and 
(2) they had been given lithium continuously for at least 
twelve months. The patients were observed for a period 
of six years and six months. Lithium was administered 
prophylactically for periods of one to five yearq, and 
dosages were adjusted to give a serum concentration in 
the range of 0.6 to 1.3 mEq/liter. All patients had 
been treated with other drugs or ECT prior to lithium 
. 
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treatment. Anti-depressant therapy was given together 
with lithium when the latter was started during a de¬ 
pression, and usually also during depressive relapses. 
For each patient, the relapse frequency (average number 
of episode starts per year) was calculated for the 
periods with and without lithium. The average duration 
of psychotic episodes was also calculated for pre-drug 
and drug periods. An "episode" was defined as a psy¬ 
chotic phase of mania or depression, or of mixed type, 
of sufficent magnitude to necessitate hospitalization 
or regular supervision at home. Part of the anamnesis 
was necessarily based on information given by patients 
and their families (specifically, for number and dura¬ 
tion of psychotic episodes from the beginning of the 
observation period—1 January, i960—until time of the 
first admission to the hospital at Glostrup). The pre¬ 
sumption of the study was that this information, although 
by nature retrospective, would be in the direction that 
too few, rather than too many, psychotic episodes would 
be registered. This would introduce a bias against 
lithium. Also, since lithium treatment was commonly 




bility of observing the pureley prophylactic action of 
lithium before the end of the episode, the lithium 
periods were counted forward from the date of termina¬ 
tion of the episode in question. This convention would 
necessarily introduce a bias for lithium, since, as 
qp 
Ottoson has argued, in counting backward the pre-drug 
period always begins with an episode, while in counting 
forward the period always begins with an episode-free 
interval. 
Comparison of relapse frequency and psychosis rate 
(number of psychotic months per year) showed highly sig¬ 
nificant decreases during lithium administration (p ^ 0.001) 
for the group as a whole, and for each diagnostic type 
individually (i.e., manic-depressive, and recurrent de¬ 
pressive psychoses). In other words, lithium prevented 
relapses with equal efficacy in patients having had both 
manias and depressions, and in patients with a history 
of depressions only. Without treatment, relapses 
occurred on an average of every eight months; but during 
treatment, every sixty to eighty-five months. Similarly, 
for the group as a whole, it was found that without treat¬ 




in a psychotic state, but during lithium treatment, less 
than two weeks per year. Interestingly, in a sub-group 
of 25 patients who had stopped taking lithium against 
psychiatric advice (and who had been without relapses or 
troublesome side effects during treatment), relapses 
occurred with the same frequency and duration as before 
lithium treatment. The prophylactic action of lithium 
was found to be independent of patient age and duration 
of illness, for the group as a whole. 
A small group of "atypical" cases (N=15), charac¬ 
terized by delusions, especially of persecution, responded 
less well (p ^ 0.05), as measured by the parameters of 
relapse frequency and psychosis rate. Paranoid ideation 
tended to persist. Among the 18 patients who relapsed 
despite continuous lithium treatment, one-third belonged 
to the group of atypical cases. Among the cases without 
relapse, only one-sixth were atypical. Since a fixed- 
dosage lithium schedule was employed, some of the re¬ 
lapses may have been due to too low a dosage of the drug. 
Increased dosage was followed by relapse-fee periods in 
four cases, with further relapses in two. Baastrup 
speculates that a time factor may have been involved 
. 
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in some of the failures. In one-third, psychotic re¬ 
lapses occurred within the first six months of treatment 
only, suggesting that in some cases chronic loading may 
be necessary to the achievement of stability. Some fail¬ 
ures may also have been due to patients' irregularity in 
following dosage schedules. 
historically, the question of lithium prophylaxsis 
was not entirely clarified by haastrup's statistical re¬ 
view. In addition to questionable methodologic biases 
(effects of patient recall, and the convention of defin¬ 
ing before- and after-periods), it is clear that the 
design is based on two further assumptions. The first 
of these is that the effect of observer bias and psycho¬ 
logical factors (including placebo effect) would be neg¬ 
ligible under the circumstances of the trial. The second 
is that the course of the disease before treatment could 
be used as an estimate of the course to be expected dur¬ 
ing treatment if the treatment were inactive. 
Schou has discounted the alleged role of psycho¬ 
logical factors with the following assertion: "Patients 
with a severe manic-depressive psychosis are generally 
not susceptible to suggestion, and when it comes to a 
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question of the course of the illness over a number of 
years, the possibility of suggestion must be ruled out 
entirely.Blackwell has criticized the contention 
that studies in chronic depression are not subject to 
k 
placebo effects. He cites the collaborative study by 
3k 
Raskin et« al. in support of his own contention that 
a placebo produces "quite marked" benefits on a number 
of symptoms and subtypes of depression. He also cites 
an observation made in the study that drug treatment 
differences accounted for only 10% of the variance in 
outcome. 
There is some question, however, about the applica¬ 
bility of this study to the issue at hand. The study 
was designed to test the differential effects of chlor- 
promazine, imipramine, and placebo on three diagnostic 
subgroups of depression: neurotic depressives (includ¬ 
ing patients with depressive reactions), psychotic de¬ 
pressives (including patients with involutional psychotic 
reactions, manic-depressive illness, and psychotic de¬ 
pressive reactions), and schizophrenic depressives. 
Patients within a diagnostic subgroup were assigned ran¬ 
domly to a particular drug regimen, and no attempt was 
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made to assure comparability of treatment groups. The 
results are reported as the number of "psychotic” pa¬ 
tients having "high (bad)" and "low (good)" mean scores, 
by various rating scales, after a clinical trial of four 
weeks: 
good (low) high (bad) 
chlorpromazine 12 21 
imipramine 50 8 
placebo 8 39 
It is very difficult to assess the magnitude of 
placebo and drug effect from this data, since the treat¬ 
ment groups were not known to be comparable in types of 
psychotic depressive patients, in pre-treatment symptom 
scores, and in age-sex variation. Furthermore, the ob¬ 
servation that "drug-treatment differences accounted for 
only ten percent of the variance in outcome" is probably 
a reflection of the lack of diagnostic homogeneity among 
patients in a particular treatment group and variability 
of pre-treatment symptom scores. Blackwell does not 
quote the other observation made by the authors: "Over¬ 
all sub-type, age-sex, and pre-treatment symptoms score 
accounted for more than 50% of the variance in the various 

It would seem, therefore, that criterion measures." 
this study does not provide any specific or convincing 
evidence for a large placebo effect in the drug treat¬ 
ment of patients with manic-depressive psychosis. 
Blackwell is probably correct, however, in the general 
sense that placebo effect cannot be ignored in any 
attempt to assess the actual effects of psychotropic 
agents, and that definitive evidence can be provided 
only when a control or placebo group is used. He 
cites the fairly representative report by Lowinger and 
Dobie ("What makes the placebo work," Arch. Gen. 
Psychiat. 20:8U-88, 196U), which showed a placebo re¬ 
sponse rate in double-blind studies on schizophrenic 
patients of from 2b to l6 percent. 
The second issue to be raised with Baastrup's 
study concerns the inductive assumption that the course 
of the disease during the years preceding lithium treat¬ 
ment could be used as an estimate of the course to be 
expected during treatment if lithium were inactive. 
Since patients were selected on the basis of having 
experienced relapses with a frequency higher than a 
specified minimum during the last two to three years 
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before lithium, this could.—depending on the degree of 
randomness with which manic and depressive episodes 
occur—lower the frequency of episodes during the lithium 
period. 
In a later collaborative study with Angst, Weiss, 
Grof, and Baastrup,^ Schou elaborates two counter argu¬ 
ments. In the first, he cites two studies in which pa¬ 
tients were selected with similar criteria of having had 
relapses with a frequency above a certain minimum during 
a given period, and having received no prophylactic 
treatment. Ottoson et. al. (Laurel and Ottoson, "Prophy¬ 
lactic Lithium?" Lancet ii, 12^5-6, 1968; and Isaksson, 
Ottoson, and Perris, in Das Depressive Syndrome, ed. 
Hippius and Selbach, 581-7^, 1969) studied the course of 
manic-depressive patients admitted to the Umea Psychia¬ 
tric Clinic in 1983-65. Using the first admission during 
this time as the dividing point between two two-year 
periods, one preceding the admission and the other fol¬ 
lowing it, these investigators found no significant 
change in the number of episodes between the two periods. 
The tally was compiled from the histories of 62 patients 





episodes during the first two-year period. The study 
was duplicated by Angst, Grof, and Schou ("Lithium," 
Lancet i, 1907, 1969), using 37 patients with recurrent 
affective disorders. Again, comparison of the before- 
and after-periods showed no significant differences in 
the number of admissions. While the patient sample of 
these two studies may not be directly comparable with 
those used in the statistical reviews of 1967^ and 1970"^, 
the studies probably do reflect the trend in such patient 
samples, since they were chosen with similar criteria. 
The issue with Baastrup's inductive assumption has 
been elaborated by Blackwell.^ Citing the 1970 sta¬ 
tistical review by Angst, Schou, et. al.^ ("very simi¬ 
lar in design and result to Schou's 1907 review"), 
Blackwell notes—correctly—'that about half of the 
patients treated with lithium improved, while half 
showed no change or deteriorated. He also notes (from 
Table XII of the review) that the difference in episode 
frequenty between control and lithium periods is greater 
in those patients with a history of five or more previ¬ 
ous episodes. (The authors had argued that differences 
in episode frequency would necessarily be smaller in 
. 
patients with few previous episodes, and that this pre¬ 
sumably accounts for the seemingly inferior results ob¬ 
tained in patients with two to four previous episodes.) 
Blackwell continues: ’’Since the mean duration of total 
illness before lithium is 32.8 months (all patients) 
and an episode lasts six months on an average, this sug¬ 
gests that the patients showing most benefit were almost 
continuously ill (for at least 30 out of the 32.8 months). 
Since any change would then represent an improvement, 
lithium intervention has been credited with what largely 
represents the phenomenon of regression toward mean ill¬ 
ness behaviour." 
Blackwell's argument depends upon the meaning of 
"regression toward mean illness behaviour." He gives 
the following definition: "There is clearly a point 
(this side of continuous ill health) at which an ill¬ 
ness cannot do anything except stay the same or improve 
(regress toward mean illness behaviour)." Blackwell 
thus implies that the "mean illness behaviour" is in 
fact something other than the mean total duration of 
illness before lithium treatment for all patients 
(32.8 months) or the average cycle length for all 
. 
patients, or the average episode duration (6 months)." 
But he nowhere says how that mean is to he determined, 
except to imply that the 25% of patients in Schou's 
sample with two to four previous episodes more closely 
approximates it than does the 75% with five or more 
episodes. 
Schou's second counterargument to criticism of 
the inductive assumption is that there is actually a 
tendency towards a progressive shortening of cycle 
length characteristic of recurrent affective disorders. 
He cites as evidence the studies of Angst and Weis 
(in W. Schulte and W. Mende, eds.. Melancholia, 2-9, 
1969) of both manic-depressive and schizoaffective 
patients, who had received no prophylactic treatment 
and who were studied during two consecutive time 
periods. The effect of such a tendency would be to 
introduce a bias against lithium. Despite this, 
Angst and Schou report in the 1970 review^ that manic- 
depressive and recurrent-depressive cycles were found 
by regression analysis to be 6l and 7b percent longer 
during lithium than under comparable conditions with¬ 
out lithium. In schizoaffective psychosis, the 
. 
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corresponding figure was 30 percent. 
Another paper by P. C. Baastrup et. al. , involving 
double-blind discontinuation of lithium in 50 manic- 
depressive patients and 2h patients with recurrent endo¬ 
genous depression, employed an experimental design in¬ 
dependent of both assumptions involved in statistical 
reviews of 1967 and 1970. All patients had been on open 
lithium treatment for at least a year. Within each 
diagnostic group, patients were paired according to the 
total number of previous episodes. Each member of the 
pair was allocated at random to lithium carbonate or 
placebo. Thus the lithium groups did not differ sig¬ 
nificantly from the corresponding placebo groups as 
regards number of previous episodes, duration of ill¬ 
ness, mean frequency of episodes before lithium, dura¬ 
tion of open lithium treatment, and age at start of 
the trial. Relapses were recorded when patients re¬ 
quired hospitalization or supervision with additional 
therapy at home. Serum lithium was monitored to assure 
that patients took the right tablet in the right dosage. 
The advantages of the design were threefold: (l) pa¬ 





thus facilitating the maintenance of "blindness" in the 
raters, (2) maintenance lithium dosage had been adjusted 
to the most suitable level, so that little or no further 
adjustment was required, and (3) interruption of the 
trial at first relapse mean that each patient was at 
risk only for a single manic or depressed episode. 
Baastrup reports that in the manic-depressive groups, 
twelve relapses occurred among the placebo patients 
(12/22), but none among the lithium patients (0/22). 
Six of the relapses were manias, five were depressions, 
and one was mixed. In the group with recurrent depres¬ 
sions, nine relapses (all depressions) were recorded 
among the placebo patients (9/17), but none among the 
lithium patients (0/17). The mean trial duration was 
19.7 and 20.3 weeks, respectively, for manic-depressive 
patients on placebo and lithium. The corresponding 
figures for patients with recurrent depressions were 
20.9 and 19.9 weeks. The likelihood of chance occur¬ 
rence of these results is reported to be less than one 
in ten thousand (by hypergeometric distribution) for 
the manic-depressed patients, and less than one in one 




relapses occurred in nine of the eighteen placebo pa¬ 
tients who had been on lithium therapy one to three 
years, and in twelve of the twenty-one patients who had 
received lithium for four to seven years. This suggests 
that even after many years of lithium therapy, there is 
still risk of relapse upon discontinuation of the drug. 
Blackwell has raised another side of the psycho¬ 
logical issue pertinent to these results.^ He suggests 
that relapses occurring after double-blind transfer of 
patients from lithium to placebo could be caused by the 
disappearance of side effects, or by the appearance of 
withdrawal or rebound effects, including subliminal per¬ 
ception of the change in REM sleep patterns. Schou 
et. al. have argued aginst this possibility by showing 
that frequency of relapse was the same during the first 
month after transfer as during each of several succeed- 
3 7 
ing months. ' Since psychological factors would be 
strongest in the immediate witndrawal periods, this would 
suggest that (subliminal) perception of disappearance of 
side effects or of withdrawal or rebound effects does not 
account for the relapses that occur. In addition, the 




continuation with those after open discontinuation. 
The rates were IT percent per month and 15 percent per 
month, respectively. This again suggests that observer 
bias and placebo effect do not significantly effect re¬ 
lapse rate. 
The evidence reviewed suggests that lithium exerts 
a significantly beneficial action on endogenous mood 
levels, by counteracting swings toward both mania and 
depression, but the methodological problems in establish¬ 
ing this claim are considerable. They include: (l) lack 
of homogeneous diagnostic criteria and/or the application 
of same, with resulting lack of comparability of studies; 
(2) lack of reproducible, quantitative, assessment of 
both degree of psychosis and differentiated changes in 
psychotic states; (3) lack of control in retrospective 
appraisal of psychotic states; (4) the problem of ade¬ 
quate assessment of drug-induced, as opposed to spon¬ 
taneous, changes in disease course; (5) lack of compara¬ 
bility of drug and control groups of patients; (6) effects 
of observer bias on improvement ratings, and the practical 
difficulties of maintaining double-blind standards; 
(7) use of the null hypothesis in prophylactic studies. 
. 
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with the resulting neglect of placebo effects; (8) ques¬ 
tionable predictability of disease course, on the basis 
of present and past behavior; and (9) neglect of informed 
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